<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Bisphosphonate use in children with cerebral palsy - Hurley, T - 2021 | Cochrane Library</title> <meta content="Bisphosphonate use in children with cerebral palsy - Hurley, T - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012756.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Bisphosphonate use in children with cerebral palsy - Hurley, T - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012756.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012756.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Bisphosphonate use in children with cerebral palsy" name="citation_title"/> <meta content="Tim Hurley" name="citation_author"/> <meta content="Trinity College Dublin" name="citation_author_institution"/> <meta content="Zunera Zareen" name="citation_author"/> <meta content="zuneraz@yahoo.ie" name="citation_author_email"/> <meta content="Philip Stewart" name="citation_author"/> <meta content="The National Children’s Hospital" name="citation_author_institution"/> <meta content="Ciara McDonnell" name="citation_author"/> <meta content="The National Children’s Hospital, Tallaght" name="citation_author_institution"/> <meta content="Denise McDonald" name="citation_author"/> <meta content="The National Children’s Hospital" name="citation_author_institution"/> <meta content="Eleanor Molloy" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD012756.pub2" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/07/05" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012756.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012756.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012756.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Alkaline Phosphatase [blood]; Bias; Bone Density [*drug effects]; Bone Density Conservation Agents [*therapeutic use]; Cerebral Palsy [*complications]; Collagen Type I [blood]; Diphosphonates [*therapeutic use]; Fractures, Spontaneous [prevention &amp; control]; Hydroxycholecalciferols [therapeutic use]; Osteoporosis [blood, *drug therapy]; Peptides [blood]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012756.pub2&amp;doi=10.1002/14651858.CD012756.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012756.pub2&amp;doi=10.1002/14651858.CD012756.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012756.pub2&amp;doi=10.1002/14651858.CD012756.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012756.pub2&amp;doi=10.1002/14651858.CD012756.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012756.pub2&amp;doi=10.1002/14651858.CD012756.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012756.pub2&amp;doi=10.1002/14651858.CD012756.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012756.pub2&amp;doi=10.1002/14651858.CD012756.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012756.pub2&amp;doi=10.1002/14651858.CD012756.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012756.pub2&amp;doi=10.1002/14651858.CD012756.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012756.pub2&amp;doi=10.1002/14651858.CD012756.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012756.pub2&amp;doi=10.1002/14651858.CD012756.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012756.pub2&amp;doi=10.1002/14651858.CD012756.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012756.pub2&amp;doi=10.1002/14651858.CD012756.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012756.pub2&amp;doi=10.1002/14651858.CD012756.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012756.pub2&amp;doi=10.1002/14651858.CD012756.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012756.pub2&amp;doi=10.1002/14651858.CD012756.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012756.pub2&amp;doi=10.1002/14651858.CD012756.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012756.pub2&amp;doi=10.1002/14651858.CD012756.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012756.pub2&amp;doi=10.1002/14651858.CD012756.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012756.pub2&amp;doi=10.1002/14651858.CD012756.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012756.pub2&amp;doi=10.1002/14651858.CD012756.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012756.pub2&amp;doi=10.1002/14651858.CD012756.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012756.pub2&amp;doi=10.1002/14651858.CD012756.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="kKvAiZoF";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012756\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012756\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012756\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012756\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","th","ms","ja","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012756.pub2",title:"Bisphosphonate use in children with cerebral palsy",firstPublishedDate:"Jul 5, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Developmental, Psychosocial and Learning Problems Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=kKvAiZoF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012756.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012756.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012756.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012756.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012756.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012756.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012756.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012756.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012756.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012756.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2874 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012756.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012756.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012756.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012756.pub2/full#CD012756-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012756.pub2/full#CD012756-sec-0083"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012756.pub2/full#CD012756-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012756.pub2/full#CD012756-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012756.pub2/full#CD012756-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012756.pub2/full#CD012756-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012756.pub2/full#CD012756-sec-0040"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012756.pub2/full#CD012756-sec-0077"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012756.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012756.pub2/appendices#CD012756-sec-0088"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012756.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012756.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012756.pub2/media/CDSR/CD012756/table_n/CD012756StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012756.pub2/media/CDSR/CD012756/table_n/CD012756StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012756.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012756.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012756.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012756.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012756.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012756.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Bisphosphonate use in children with cerebral palsy</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012756.pub2/information#CD012756-cr-0004">Tim Hurley</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012756.pub2/information#CD012756-cr-0005"><i class="icon corresponding-author fa fa-envelope"></i>Zunera Zareen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012756.pub2/information#CD012756-cr-0006">Philip Stewart</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012756.pub2/information#CD012756-cr-0007">Ciara McDonnell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012756.pub2/information#CD012756-cr-0008">Denise McDonald</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012756.pub2/information#CD012756-cr-0009">Eleanor Molloy</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/information/en#CD012756-sec-0116">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 05 July 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012756.pub2">https://doi.org/10.1002/14651858.CD012756.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012756-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012756-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012756-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012756-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012756-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD012756-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012756-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012756-abs-0001" lang="en"> <section id="CD012756-sec-0001"> <h3 class="title" id="CD012756-sec-0001">Background</h3> <p>Cerebral palsy (CP) is a heterogeneous group of non‐progressive disorders of posture or movement, caused by a lesion of the developing brain. Osteoporosis is common in children with cerebral palsy, particularly in children with reduced gross motor function, and leads to an increased risk of fractures. Gross motor function in children with CP can be categorised using a tool called the Gross Motor Function Classification System (GMFCS). Bisphosphonate increases bone mineral density (BMD) and reduces fracture rates. Bisphosphonate is used widely in the treatment of adult osteoporosis. However, the use of bisphosphonate in children with CP remains controversial, due to a paucity of evidence and a lack of recent trials examining the efficacy and safety of bisphosphonate use in this population. </p> </section> <section id="CD012756-sec-0002"> <h3 class="title" id="CD012756-sec-0002">Objectives</h3> <p>To examine the efficacy and safety of bisphosphonate therapy in the treatment of low BMD or secondary osteoporosis (or both) in children with cerebral palsy (GMFCS Levels III to V) who are under 18 years of age. </p> </section> <section id="CD012756-sec-0003"> <h3 class="title" id="CD012756-sec-0003">Search methods</h3> <p>In September 2020, we searched CENTRAL, MEDLINE, Embase, six other databases, and two trial registers for relevant studies. We also searched the reference lists of relevant systematic reviews, trials, and case studies identified by the search, and contacted the authors of relevant studies in an attempt to identify unpublished literature. </p> </section> <section id="CD012756-sec-0004"> <h3 class="title" id="CD012756-sec-0004">Selection criteria</h3> <p>All relevant randomised controlled trials (RCTs), and quasi‐RCTs, comparing at least one bisphosphonate (given at any dose, orally or intravenously) with placebo or no drug, for the treatment of low BMD or osteoporosis in children up to 18 years old, with cerebral palsy (GMFCS Levels III to V). </p> </section> <section id="CD012756-sec-0005"> <h3 class="title" id="CD012756-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane. We were unable to conduct any meta‐analyses due to insufficient data, and therefore provide a narrative assessment of the results. </p> </section> <section id="CD012756-sec-0006"> <h3 class="title" id="CD012756-sec-0006">Main results</h3> <p>We found two relevant RCTs (34 participants). Both studies included participants with non‐ambulatory CP or CP and osteoporosis. Participants in both studies were similar in severity of CP, age distribution, and sex distribution. The two trials used different bisphosphonate medications and different intervention durations, but further comparison of the interventions was not possible due to a lack of published data from one trial. </p> <p>One trial received funding and support from research, academic, and hospital foundations, with pharmaceutical companies providing components of the calcium and vitamin supplement; the other trial did not report sources of funding. We judged one study at an overall high risk of bias; the other as overall unclear risk of bias. </p> <p><b>Primary outcome.</b> Compared to placebo or no treatment, both studies provided very low certainty evidence of improved BMD at least four months post‐intervention in children treated with bisphosphonate. Only one study (12 participants) provided sufficient detail to assess a measure of the effect, and reported an improvement at six months post‐intervention in lumbar spine z‐score (mean difference (MD) 18%, 95% confidence interval (CI) 6.57 to 29.43; very low certainty evidence). </p> <p><b>Secondary outcomes.</b> Very low certainty evidence from one study found that bisphosphonate reduced serum N‐telopeptides (NTX) more than placebo; the other study reported that both bisphosphonate plus alfacalcidol and alfacalcidol alone reduced NTX, but did not compare groups. </p> <p>One study reported inconclusive results between groups for serum bone‐specific alkaline phosphatase (BAP). The other study reported that both bisphosphonate plus alfacalcidol and alfacalcidol alone reduced BAP, but did not compare groups. </p> <p>Neither study reported data for the effect of bisphosphonate treatment on changes in volumetric BMD in the distal radius or tibia, changes in fracture frequency, bone pain, or quality of life. One study reported that two participants had febrile events noted during their first dosing schedule, but no further adverse events were reported in either relevant study. </p> </section> <section id="CD012756-sec-0007"> <h3 class="title" id="CD012756-sec-0007">Authors' conclusions</h3> <p>Based on the available evidence, there is very low certainty evidence that bisphosphonate treatment may improve bone health in children with cerebral palsy. We could only include one study with 14 participants in the assessment of the effect size; therefore, the precision of the effect estimate is low. We could only evaluate one planned primary outcome, as there was insufficient detail reported in the relevant studies. </p> <p>Further research from RCTs on the effect and safety of bisphosphonate to improve bone health in children with cerebral palsy is required. These studies should clarify the optimal standard treatment regarding weight‐bearing exercises, vitamin D and calcium supplementation, and should include fracture frequency as a primary outcome. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012756-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012756-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012756-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012756-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012756-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD012756-abs-0010">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012756-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD012756-abs-0015">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012756-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD012756-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012756-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012756-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012756-abs-0002" lang="en"> <h3>Bisphosphonate treatment to improve bone health in children with cerebral palsy</h3> <p><b>Why is this review important?</b> </p> <p>Poor bone strength is common in people with cerebral palsy (CP). Causes include: reduced weight‐bearing activities that build bone strength, such as walking or running, particularly among people who require mobility assistance devices; reduced intake of vitamins and minerals that increase bone strength, including calcium and vitamin D; and increased use of medications that prevent bone formation, such as anti‐seizure medications. This leads to a high risk of bone fractures, even with very mild trauma. Children with CP who are unable to walk are at particularly high risk of poor bone strength and fractures in the leg bones. Bisphosphonates are a group of medications that are used to improve bone strength. Bisphosphonates are commonly used in adults with poor bone strength. However, there is a lack of evidence for their use in children. </p> <p><b>What questions does this review aim to answer?</b> </p> <p>First, what is the effect of bisphosphonate treatment compared to placebo (dummy pill) or no treatment on different measures of bone strength in children up to 18 years with CP? Measures include blood markers of bone health, fracture frequency, bone pain, and quality of life. </p> <p>Second, are there any negative side effects?</p> <p><b>Which studies were included in the review?</b> </p> <p>We examined the available evidence for the use of bisphosphonate treatment in children with CP up to September 2020. We found two trials that compared the use of bisphosphonate treatment with placebo or no treatment to improve bone strength in children with CP. These two trials included a total of 34 participants with CP of similar levels of severity. Participants in both studies were 16 years of age or under, and there were equal numbers of boys and girls in each trial. Both trials included children who were unable to walk. The two trials used different types of bisphosphonate treatments, given for six months in one study and 12 months in the other. Further comparison of these treatments was not possible due to a lack of published information in one trial. </p> <p>One trial was supported by research, academic and hospital foundations, with pharmaceutical companies donating components of the calcium and vitamin supplements. The other study did not report their funding sources. </p> <p><b>What does the evidence from the review reveal?</b> </p> <p>Results from both trials provide some evidence that giving children with CP bisphosphonate treatment for at least six months, may improve their bone strength. The strength of this effect could only be measured in one trial with 12 participants. This suggested an average improvement in bone strength of 18%, measured by bone mineral density (BMD). However, because of the very small number of participants in both trials, the wide variation in results, and some problems with the way the trials were conducted, this conclusion is uncertain. </p> <p>Each study reported the results of changes in blood markers of bone strength in a different way, meaning we have inconclusive evidence, and cannot draw conclusions regarding the effects of bisphosphonate treatment. </p> <p>Neither trial reported any significant risks or serious adverse outcomes among the children undergoing bisphosphonate treatment. </p> <p>Neither trial examined the question of whether bisphosphonate treatment had an effect on changes in actual bone density, nor the rate of fractures of children with CP.  </p> <p><b>Author conclusions</b> </p> <p>We have limited confidence as to whether bisphosphonate treatment may improve bone health in children with CP. </p> <p>Further studies are required to assess the benefit and risks of bisphosphonate treatment in children with CP. Future studies of bisphosphonate should examine the effects of bisphosphonate combined with other new treatment options. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012756-sec-0083" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012756-sec-0083"></div> <h3 class="title" id="CD012756-sec-0084">Implications for practice</h3> <section id="CD012756-sec-0084"> <p>There is very low certainty evidence to suggest that, compared to placebo or no treatment, bisphosphonate therapy may improve BMD in the lumbar spine and distal femur in children with cerebral palsy and low BMD or osteoporosis. There were minimal adverse effects reported following 12 months of bisphosphonate treatment; however, the sample size in this study was very small. There is no evidence that assesses whether bisphosphonate treatment may reduce fracture frequency or improve bone pain and quality of life in this population. </p> </section> <h3 class="title" id="CD012756-sec-0085">Implications for research</h3> <section id="CD012756-sec-0085"> <p>We believe that further research from randomised trials is required to answer, more conclusively, the question of whether bisphosphonate treatment improves bone health in people with cerebral palsy and low BMD or osteoporosis. This research should include methodology to assess the optimum types of bisphosphonate, dosing concentration, method of administration, and frequency schedule, as there is currently insufficient evidence to answer these questions. RCTs should stratify children by severity of cerebral palsy (by Gross Motor Function Classification System (GMFCS) classification). Research could also explore risk factors for poor bone density, including comorbidites, and the use of medications, such as anti‐epileptic drugs. Future trials should focus on the effectiveness of newer, third generation bisphosphonates. There is no evidence regarding the duration of treatment, but it has been suggested that if there is no benefit after two years of bisphosphonate treatment, it should be discontinued. Future trials are required to answer this question. We believe that when designing any study of an intervention to improve bone health in children with cerebral palsy, there should be a greater focus on primary outcomes that include the evaluation of fracture frequency, bone pain, and quality of life using validated evaluation or scoring systems. Consistency in outcome reporting methodology would provide greater opportunities to compare studies and draw stronger conclusions from further systematic or Cochrane Reviews. </p> <p>The evidence for our conclusions for this review derives from two studies conducted over 10 years ago. Since then, several studies have evaluated alternative treatments to improve bone health in this population, including weight‐bearing activities and vitamin D, with or without calcium supplementation. To date, the most recent and best available consensus recommendation regarding these alternative treatments has been published by <a href="./references#CD012756-bbs2-0064" title="SimmPJ , BigginA , ZacharinMR , RoddaCP , ThamE , SiafarikasA , et al. Consensus guidelines on the use of bisphosphonate therapy in children and adolescents. Journal of Paediatrics and Child Health2018;54(3):223-33. [DOI: 10.1111/jpc.13768] [PMID: 29504223]">Simm 2018</a>, and these should be considered when designing standard treatment protocols and comparison groups in future trials. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012756-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012756-sec-0008"></div> <div class="table" id="CD012756-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Bisphosphonate treatment (oral or intravenous) compared to placebo or no treatment for children under the age of 18 with cerebral palsy (GMFCS levels III to V)</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Bisphosphonate treatment (oral or intravenous) compared to placebo or no treatment for children under the age of 18 with cerebral palsy (GMFCS levels III to V)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> children under the age of 18 with cerebral palsy (GMFCS levels III to V)<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> bisphosphonate treatment (oral or intravenous)<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> </p> <p><b>(Studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo or no treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with bisphosphonate treatment (oral or intravenous)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in BMD lumbar spine</b> </p> <p><i>(%, assessed at 6 months post‐intervention)</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean % change in BMD lumbar spine was 15% (SE ± 5%)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean % change in BMD lumbar spine was 18% larger in the intervention group<br/>(CI 6.57% higher to 29.43% higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in volumetric BMD of distal radius or tibia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured in any trial</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in fracture frequency</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured in any trial</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p><i>(ongoing reporting, up to 6 months post‐intervention)</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>2 of 6 participants receiving their 1st 3‐day pamidronate dosing session had elevated axillary temperature (&gt; 37 °C), but not during any subsequent dosing session. </p> <p>Participants receiving placebo treatment recorded no elevation in body temperature during the 1st dosing session but was noted in 4 subsequent sessions. </p> <p>No differences in white blood cell count were noted between treatment groups.</p> <p>No other adverse events were reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in NTX</b> </p> <p><i>(assessed 4 to 6 months post‐intervention)</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>One study reported that bisphosphonate reduced serum NTX more than placebo; the other study reported that both bisphosphonate and no treatment reduced NTX (r = 0.89, P &lt; 0.001 versus r = 0.69, P = 0.003), but did not compare groups. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in BAP</b> </p> <p><i>(assessed 4 to 6 months post‐intervention)</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>One study reported inconclusive results between groups for BAP. The other study reported that both bisphosphonate and no treatment reduced BAP (r = 0.89, P = 0.02 versus r = 0.72, P = &lt; 0.001), but did not compare groups. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the risk in the placebo or no treatment group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>BAP:</b> bone‐specific alkaline phosphatase; <b>BMD:</b> bone mineral density; <b>CI:</b> confidence interval; <b>GMFCS:</b> Gross Motor Function Classification System; <b>MD:</b> mean difference; <b>NTX:</b> N‐telopeptides; <b>RCT:</b> randomised controlled trial; <b>SE:</b> standard error </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Certainty of evidence was downgraded by two levels, one study was at high risk of bias and one study was at unclear risk of bias.<br/><sup>b</sup>Certainty of evidence was downgraded by one level, as the results included very wide CIs, and the precision of results was deemed to be very low. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012756-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012756-sec-0009"></div> <p>Cerebral palsy is a heterogeneous group of non‐progressive disorders of posture or movement, due to an injury or lesion of the developing brain. Cerebral palsy is the most common form of childhood disability, with worldwide incidence rates between 1.5 and 4 per 1000 live births (<a href="./references#CD012756-bbs2-0057" title="PharoahPO , CookeT , JohnsonMA , KingR , MutchL . Epidemiology of cerebral palsy in England and Scotland, 1984–9. Archives of Disease in Childhood. Fetal and Neonatal Edition1998;79(1):F21-5. [PMC1720819] [PMID: 9797620]">Pharoah 1998</a>; <a href="./references#CD012756-bbs2-0058" title="ReddihoughDS , CollinsKJ . The epidemiology and causes of cerebral palsy. Australian Journal of Physiotherapy2003;49(1):7-12. [PMID: 12600249]">Reddihough 2003</a>; <a href="./references#CD012756-bbs2-0065" title="StanleyF . Cerebral palsy and newborn care: I, II, and III (1981). Developmental Medicine and Child Neurology2008;50(12):886. [DOI: 10.1111/j.1469-8749.2008.03180.x] [PMID: 19046182]">Stanley 2008</a>; <a href="./references#CD012756-bbs2-0066" title="StavskyM , MorO , MastroliaSA , GreenbaumS , ThanNG , ErezO . Cerebral palsy — trends in epidemiology and recent development in prenatal mechanisms of disease, treatment, and prevention. Frontiers in Pediatrics2017;13(5):21. [DOI: 10.3389/fped.2017.00021] [PMC5304407] [PMID: 28243583]">Stavsky 2017</a>). The prevalence of moderate to severe cerebral palsy in Europe, defined by the Gross Motor Function Classification System (GMFCS) Levels III to V, indicating a range of a child's ability to walk, from walking using a hand‐held mobility device to children who are transported using a mobility device in all settings, or an intellectual quotient less than 50, is approximately 0.78 per 1000 live births (<a href="./references#CD012756-bbs2-0062" title="SellierE , PlattMJ , AndersenGL , Krägeloh‐MannI , De La CruzJ , CansC , et al. Decreasing prevalence in cerebral palsy: a multi‐site European population‐based study, 1980 to 2003. Developmental Medicine and Child Neurology2016;58(1):85-92. [DOI: 10.1111/dmcn.12865] [PMID: 26330098]">Sellier 2016</a>). </p> <p>Several risk factors are involved in the development of cerebral palsy, which can occur during pregnancy, at birth, or after birth. These include maternal infections, premature birth, low birth weight, disruption of oxygen or blood supply to the brain, and infections or injury in the neonatal period and in early childhood, resulting in abnormalities in brain development that lead to cerebral palsy. </p> <section id="CD012756-sec-0010"> <h3 class="title" id="CD012756-sec-0010">Description of the condition</h3> <p>Osteoporosis is common in children with cerebral palsy. Osteoporosis is a condition characterised by reductions in bone strength, leading to an increased risk of fractures (<a href="./references#CD012756-bbs2-0054" title="National Institutes of Health Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA2001;285(6):785-95. [DOI: 10.1001/jama.285.6.785] [PMID: 11176917]">NIH 2001</a>). Several factors increase the risk of osteoporosis in children with cerebral palsy, including reduced weight‐bearing activities that improve bone mineral density (BMD), nutritional deficiencies of calcium and vitamin D, decreased sun exposure, and increased exposure to medications that cause low BMD, including anti‐epileptic drugs and glucocorticoids (<a href="./references#CD012756-bbs2-0050" title="KoA , KongJ , SamadovF , MukhamedovA , KimYM , LeeYJ , et al. Bone health in pediatric patients with neurological disorders. Annals of Pediatric Endocrinology &amp; Metabolism2020;25(1):15-23.">Ko 2020</a>). The prevalence of low BMD in children with severe cerebral palsy is 77% (95% confidence interval (CI) 65.0% to 87.1%) and the annual incidence rate of fractures is 4% (<a href="./references#CD012756-bbs2-0051" title="MerglerS , EvenhuisHM , BootAM , De ManSA , Bindels-De HeusKG , HuijbersWA , et al. Epidemiology of low bone mineral density and fractures in children with severe cerebral palsy: a systematic review. Developmental Medicine and Child Neurology2009;51(10):773–8. [DOI: 10.1111/j.1469-8749.2009.03384.x] [PMID: 19614941]">Mergler 2009</a>). A longitudinal assessment of changes in bone density in adolescents with cerebral palsy reported an annual increase in areal BMD (aBMD) of 4% to 8%, similar to that in typically developing children (<a href="./references#CD012756-bbs2-0069" title="TrinhA , WongP , FaheyMC , BrownJ , StraussBJ , EbelingPR , et al. Longitudinal changes in bone density in adolescents and young adults with cerebral palsy: a case for early intervention. Clinical Endocrinology2019;91(4):517-24.">Trinh 2019</a>). This finding is also reflected in the stability of the z‐score in children with cerebral palsy over time. This was a retrospective study of young people with cerebral palsy at risk of low BMD, all of whom had a z‐score less than −2 at the time of first assessment, at a mean age of 13.9 (± 3.1) years. This suggests that the deficit in bone mass is accrued during the first decade of life, so earlier interventions may be of greatest benefit. Many of those who sustain a fracture will sustain repeated fractures (<a href="./references#CD012756-bbs2-0001" title="HendersonRC , LarkRK , KecskemethyHH , MillerF , HarckeHT , BachrachSJ . Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. Journal of Pediatrics2002;141(5):644-51. [DOI: 10.1067/mpd.2002.128207] [PMID: 12410192]">Henderson 2002</a>; <a href="./references#CD012756-bbs2-0051" title="MerglerS , EvenhuisHM , BootAM , De ManSA , Bindels-De HeusKG , HuijbersWA , et al. Epidemiology of low bone mineral density and fractures in children with severe cerebral palsy: a systematic review. Developmental Medicine and Child Neurology2009;51(10):773–8. [DOI: 10.1111/j.1469-8749.2009.03384.x] [PMID: 19614941]">Mergler 2009</a>). The most common site of fracture is the distal femur (<a href="./references#CD012756-bbs2-0037" title="FehlingsD , SwitzerL , AgarwalP , WongC , SorchettE , StevensonR , et al. Informing evidence-based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis: a systematic review. Developmental Medicine and Child Neurology2012;54(2):106-16. [DOI: 10.1111/j.1469-8749.2011.04091.x] [PMID: 22111966]">Fehlings 2012</a>). Prevalence of femur fractures has been variably estimated at 14% in children with severe cerebral palsy (<a href="./references#CD012756-bbs2-0070" title="Uddenfeldt WortU , NordmarkE , WagnerP , DüppeH , WestbomL . Fractures in children with cerebral palsy: a total population study. Developmental Medicine and Child Neurology2013;55(9):821-6. [DOI: 10.1111/dmcn.12178] [PMID: 23750743]">Uddenfeldt 2013</a>). The incidence of fracture in children with severe cerebral palsy has been reported to be from 7% to 9.7% per year (<a href="./references#CD012756-bbs2-0067" title="StevensonRD , ConawayM , BarringtonJW , CuthillSL , WorleyG , HendersonRC . Fracture rate in children with cerebral palsy. Paediatric Rehabilitation2006;9(4):396-403. [PMID: 17111566]">Stevenson 2006</a>). Severe cerebral palsy is defined as Level IV or V, according to the GMFCS, and a history of clinically‐diagnosed cerebral palsy (<a href="./references#CD012756-bbs2-0056" title="PalisanoRJ , HannaSE , RosenbaumPL , RussellDJ , WalterSD , WoodEP , et al. Validation of a model of gross motor function for children with cerebral palsy. Physical Therapy2000;80(10):974-85. [PMID: 11002433]">Palisano 2000</a>; <a href="./references#CD012756-bbs2-0059" title="ReidSM , CarlinJB , ReddihoughDS . Using the Gross Motor Function Classification System to describe patterns of motor severity in cerebral palsy. Developmental Medicine &amp; Child Neurology2011;53(11):1007-12. [DOI: 10.1111/j.1469-8749.2011.04044.x] [PMID: 22014320]">Reid 2011</a>). The GMFCS is a tool used frequently in children with cerebral palsy, which assesses the independent mobility and function of children according to chronological age (<a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011937/full#CD011937-bbs2-0046" target="_blank">Palisano 2000</a>). A full description of the GMFCS is presented in <a href="./appendices#CD012756-sec-0089">Appendix 1</a>. </p> <p>The cause of low BMD in children with severe cerebral palsy is multifactorial, including impaired weight‐bearing mobilisation, less exposure to sunlight, poor growth and nutrition, and the use of anticonvulsants. Bone mineralisation is also adversely affected by the use of anticonvulsants (<a href="./references#CD012756-bbs2-0001" title="HendersonRC , LarkRK , KecskemethyHH , MillerF , HarckeHT , BachrachSJ . Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. Journal of Pediatrics2002;141(5):644-51. [DOI: 10.1067/mpd.2002.128207] [PMID: 12410192]">Henderson 2002</a>). The most commonly used method to assess BMD in children is dual x‐ray absorptiometry (DXA). This offers many practical advantages, including rapid scanning time, easy and wide availability, and low use of radiation (<a href="./references#CD012756-bbs2-0032" title="BoyceAM , TosiLL , PaulSM . Bisphosphonate treatment for children with disabling conditions. PM &amp; R: The Journal of Injury, Function, and Rehabilitation2014;6(5):427–36. [DOI: 10.1016/j.pmrj.2013.10.009] [PMC4037384] [PMID: 24368091]">Boyce 2014</a>). The results of DXA are expressed as z‐scores, calculated from age, gender, and ethnicity‐adjusted norms, and are derived from normative databases specific to the brand of densitometer used (<a href="./references#CD012756-bbs2-0074" title="ZemelBS , KalkwarfHJ , GilsanzV , LappeJM , OberfieldS , ShepherdJA , et al. Revised reference curves for bone mineral content and areal bone mineral density according to age and sex for black and non-black children: results of the bone mineral density in childhood study. Journal of Clinical Endocrinology and Metabolism2011;96(10):3160-9. Erratum in: Journal of Clinical Endocrinology and Metabolism. 2013 Jan;98(1):420. DOI: 10.1210/jc.2012-3878. [DOI: 10.1210/jc.2011-1111] [PMCID: PMC3200252] [PMID: 21917867]">Zemel 2011</a>; <a href="./references#CD012756-bbs2-0030" title="Errata. Journal of Clinical Endocrinology &amp; Metabolism2013;98(1):420: Erratum for: Journal of Clinical Endocrinology &amp; Metabolism. 2011 Oct; 96(10):3160-9. DOI: 10.1210/jc.2011-1111. [DOI: 10.1210/jc.2012-3878]">Anonymous 2013</a>). </p> <p>Treatment involves conservative measures, including optimising the management of underlying conditions, maintaining appropriate calcium and vitamin D intake, encouraging weight‐bearing physical activity, and medications, such as bisphosphonate. Guidelines published for the management of bone health in this population have reported probable evidence for bisphosphonate, possible evidence for vitamin D and calcium, and not enough evidence for weight‐bearing activities, as effective interventions to improve BMD (<a href="./references#CD012756-bbs2-0037" title="FehlingsD , SwitzerL , AgarwalP , WongC , SorchettE , StevensonR , et al. Informing evidence-based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis: a systematic review. Developmental Medicine and Child Neurology2012;54(2):106-16. [DOI: 10.1111/j.1469-8749.2011.04091.x] [PMID: 22111966]">Fehlings 2012</a>). Important effects on low BMD have been observed in small and diverse cohorts of children with cerebral palsy, using both a medical and a physical approach (<a href="./references#CD012756-bbs2-0009" title="CohranV , CassedyA , HawkinsA , BeanJ , HeubiJ . Oral risedronate sodium improves bone mineral density in non-ambulatory patients: a randomized, double-blind, placebo controlled trial. Journal of Pediatric Rehabilitation Medicine2013;6(2):85-93. [DOI: 10.3233/PRM-130242] [PMID: 23803341]">Cohran 2013</a>). However, it is unclear whether small sample sizes or variable treatment responses account for the non‐significant findings, and thus additional, large randomised controlled trials (RCTs) are needed (<a href="./references#CD012756-bbs2-0046" title="HoughJP , BoydRN , KeatingJL . Systematic review of interventions for low bone mineral density in children with cerebral palsy. Paediatrics2010;125(3):670-8. [DOI: 10.1542/peds.2009-0292] [PMID: 20123765]">Hough 2010</a>). </p> </section> <section id="CD012756-sec-0011"> <h3 class="title" id="CD012756-sec-0011">Description of the intervention</h3> <p>Bisphosphonate increases BMD, and reduces fracture rates by inactivating osteoclasts (large multinucleated cells that degrade or reabsorb bone), which are responsible for the breakdown of existing bone cells. Bisphosphonate is used widely in the treatment of adult osteoporosis, but its use in children is controversial, because of a lack of long‐term safety and efficacy data (<a href="./references#CD012756-bbs2-0003" title="AllingtonN , VivegnisD , GerardP . Cyclic administration of pamidronate to treat osteoporosis in children with cerebral palsy or a neuromuscular disorder: a clinical study. Acta Orthopaedica Belgica2005;71(1):91-7. [PMID: 15792214]">Allington 2005</a>; <a href="./references#CD012756-bbs2-0032" title="BoyceAM , TosiLL , PaulSM . Bisphosphonate treatment for children with disabling conditions. PM &amp; R: The Journal of Injury, Function, and Rehabilitation2014;6(5):427–36. [DOI: 10.1016/j.pmrj.2013.10.009] [PMC4037384] [PMID: 24368091]">Boyce 2014</a>; <a href="./references#CD012756-bbs2-0064" title="SimmPJ , BigginA , ZacharinMR , RoddaCP , ThamE , SiafarikasA , et al. Consensus guidelines on the use of bisphosphonate therapy in children and adolescents. Journal of Paediatrics and Child Health2018;54(3):223-33. [DOI: 10.1111/jpc.13768] [PMID: 29504223]">Simm 2018</a>). </p> <p>It should be noted that the primary defect of bones in cerebral palsy is a limitation in bone formation, which would respond best to anabolic therapies, for example, teriparatide. However, current guidelines do not support the use of anabolic therapies in growing bone, due to concerns related to osteosarcoma, which was identified in rats in a clinical trial setting (<a href="./references#CD012756-bbs2-0072" title="VahleJL , SatoM , LongGG , YoungJK , FrancisPC , EngelhardtJA , et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicologic Pathology2002;30(3):312-21. [DOI: 10.1080/01926230252929882] [PMID: 12051548]">Vahle 2002</a>). Thus, bisphosphonate remains the most practical alternative therapy available to children with cerebral palsy for the treatment of osteoporosis. </p> <p>Very few short‐term side effects have been reported with bisphosphonate use. Many studies have reported symptoms, including fever, malaise, and flu‐like symptoms, after the first infusion of bisphosphonate. In addition, children have also experienced gastrointestinal symptoms, including nausea, vomiting, and abdominal pain. Other possible adverse effects reported were hypocalcaemia, hypophosphataemia, bone pain, transient uveitis, acute renal tubular necrosis, nephrocalcinosis, and delayed fracture healing. Duration of bisphosphonate use is an important factor, as long‐term use (more than five years) in adults has been associated with an increased incidence of atypical femoral fractures (<a href="./references#CD012756-bbs2-0063" title="ShaneE , BurrD , AbrahamsenB , AdlerRA , BrownTD , CheungAM , et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research2014;29(1):1-23. [DOI: 10.1002/jbmr.1998] [PMID: 23712442]">Shane 2013</a>). It is unclear whether there are significant risks of adverse effects from long‐term use of bisphosphonate in children. A retrospective review of eight children with spinal muscular atrophy and low BMD, who received bisphosphonate therapy for over one year, reported an atypical femoral fracture in one child (<a href="./references#CD012756-bbs2-0053" title="NasomyontN , HornungLN , WassermanH . Intravenous bisphosphonate therapy in children with spinal muscular atrophy. Osteoporosis International2020;31(5):995-1000.">Nasomyont 2020</a>). A case report identified a child with idiopathic juvenile arthritis and low BMD, who received bisphosphonate treatment for two years, and developed an atypical femoral fracture (<a href="./references#CD012756-bbs2-0033" title="BoyceAM , CollinsMT , TosiLL , GafniRI . A subtrochanteric femoral stress fracture following bisphosphonate treatment in an adolescent girl. Hormone Research in Paediatrics2017;87(1):69-72.">Boyce 2017</a>). Outside of these two small studies, it is unclear if long‐term bisphosphonate treatment conveys a significant risk of atypical femoral fractures in this population. Osteonecrosis of the jaw has also been linked with long‐term bisphosphonate use in adults, but not in children, and with use in settings with poor dental hygiene (<a href="./references#CD012756-bbs2-0048" title="KhoslaS , BurrD , CauleyJ , DempsterDW , EbelingPR , FelsenbergD , et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research2007;22(10):1479-91. [10.1359/jbmr.0707onj] [17663640]">Khosla 2007</a>). </p> <p>Cochrane Reviews by <a href="./references#CD012756-bbs2-0035" title="DwanK , PhillipiCA , SteinerRD , BaselD . Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD005088. [DOI: 10.1002/14651858.CD005088.pub3]">Dwan 2014</a> and <a href="./references#CD012756-bbs2-0073" title="WardL , TriccoA , PhuongPN , CranneyA , BarrowmanN , GabouryI , et al. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database of Systematic Reviews2007, Issue 4. Art. No: CD005324. [DOI: 10.1002/14651858.CD005324.pub2]">Ward 2007</a> concluded that there were insufficient data to support the use of bisphosphonate as standard therapy in children. However, over the past few decades, bisphosphonate use in children has increased, especially in the treatment of osteogenesis imperfecta (OI). <a href="./references#CD012756-bbs2-0035" title="DwanK , PhillipiCA , SteinerRD , BaselD . Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD005088. [DOI: 10.1002/14651858.CD005088.pub3]">Dwan 2014</a> included randomised controlled trials (RCT) that provided evidence that bisphosphonate improved BMD, reduced fracture risk, and improved pain in children with OI. </p> </section> <section id="CD012756-sec-0012"> <h3 class="title" id="CD012756-sec-0012">How the intervention might work</h3> <p>Bisphosphonates are a synthetic analogue of pyrophosphate, an endogenous regulator of bone metabolism. They increase BMD by inhibiting osteoclast activity or by inducing osteoclast apoptosis (<a href="./references#CD012756-bbs2-0071" title="UkonY , MakinoT , KodamaJ , TsukazakiH , TateiwaD , YoshikawaH , et al. Molecular-based treatment strategies for osteoporosis: a literature review. International Journal of Molecular Sciences2019;20(10):2557. [DOI: 10.3390/ijms20102557] [PMC6567245] [PMID: 31137666]">Ukon 2019</a>). Bisphosphonate can be administered via the oral or intravenous (IV) route, but as oromotor dysfunction, or gastrointestinal reflux (or both) are often associated with cerebral palsy, oral administration may not be safe or advisable in this group (<a href="./references#CD012756-bbs2-0068" title="SullivanPB . Gastrointestinal disorders in children with neurodevelopmental disabilities. Developmental Disabilities Research Reviews2008;14(2):128-36. [DOI: 10.1002/ddrr.18] [PMID: 18646021]">Sullivan 2008</a>). Thus, it is preferable to use IV formulations of bisphosphonate in the treatment of osteoporosis in children with cerebral palsy. </p> <p>Clinical issues under consideration that relate to the use of bisphosphonate, include the choice of therapeutic regimen (e.g. the use of intermittent dosing rather than continuous, IV dosing versus oral therapy), the optimal duration of therapy, the combination with other drugs, such as teriparatide, and their extended use in other related conditions, including glucocorticosteroid‐associated osteoporosis, childhood osteopenic disorders, and arthritis (<a href="./references#CD012756-bbs2-0061" title="RussellRG . Bisphosphonates: the first 40 years. Bone2011;49(1):2-19. [DOI: 10.1016/j.bone.2011.04.022] [PMID: 21555003]">Russell 2011</a>). A recent retrospective review of bisphosphonate treatment to prevent recurrent fractures in 32 children with cerebral palsy reported a post‐treatment reduction in fracture frequency from 2.4 fractures per year to 0.1 fractures per year, with an average follow‐up time of 6.4 years (<a href="./references#CD012756-bbs2-0026" title="SeesJP , SitoulaP , DabneyK , Holmes L Jr, RogersKJ , KecskemethyHH , et al. Pamidronate treatment to prevent reoccurring fractures in children with cerebral palsy. Journal of Pediatric Orthopedics2016;36(2):193-7. [DOI: 10.1097/BPO.0000000000000421] [PMID: 25757207]">Sees 2016</a>). Only 11 children (34%) sustained a fracture post‐treatment. </p> <p>Several bisphosphonates are available for use in adults, including etidronate (Didronel), pamidronate (Aredia), alendronate (Fosamax), ibandronate (Boniva), and risedronate (Actonel), but few are effective and safe to use in children. Pamidronate, in particular, has proved remarkably effective in increasing bone in children with the inherited 'brittle‐bone' disorder, osteogenesis imperfecta. However, more recent guidelines often recommend the use of pamidronate for children under two years old, with OI, before switching to zoledronate in older children (<a href="./references#CD012756-bbs2-0064" title="SimmPJ , BigginA , ZacharinMR , RoddaCP , ThamE , SiafarikasA , et al. Consensus guidelines on the use of bisphosphonate therapy in children and adolescents. Journal of Paediatrics and Child Health2018;54(3):223-33. [DOI: 10.1111/jpc.13768] [PMID: 29504223]">Simm 2018</a>). A recent retrospective review on the use of zoledronic acid (ZA) for 81 young people under 21 years old, with bone disorders, reported that ZA‐related adverse events were common, particularly after the first infusion and in bisphosphonate‐naive people, but were typically mild and easily managed (<a href="./references#CD012756-bbs2-0038" title="GeorgeS , WeberDR , KaplanP , HummelK , MonkHM , LevineMA . Short-term safety of zoledronic acid in young patients with bone disorders: an extensive institutional experience. Journal of Clinical Endocrinology and Metabolism2015;100(11):4163-71. [DOI: 10.1210/jc.2015-2680] [PMC4702447] [PMID: 26308295]">George 2015</a>). Both pamidronate and risedronate have been used in controlled trials of bisphosphonate conducted with children with cerebral palsy (<a href="./references#CD012756-bbs2-0001" title="HendersonRC , LarkRK , KecskemethyHH , MillerF , HarckeHT , BachrachSJ . Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. Journal of Pediatrics2002;141(5):644-51. [DOI: 10.1067/mpd.2002.128207] [PMID: 12410192]">Henderson 2002</a>; <a href="./references#CD012756-bbs2-0002" title="IwasakiT , TakeiK , NakamuraS , HosodaN , YokotaY , IshiiM . Secondary osteoporosis in long-term bedridden patients with cerebral palsy. Pediatrics international2008;50(3):269-75. [DOI: 10.1111/j.1442-200X.2008.02571.x] [PMID: 18533934]">Iwasaki 2008</a>; <a href="./references#CD012756-bbs2-0047" title="IwasakiT , NonodaY , IshiiM . Long-term outcomes of children and adolescents who had cerebral palsy with secondary osteoporosis. Current Medical Research and Opinion2012;28(8):737-47. [DOI: 10.1185/03007995.2011.645562] [PMID: 22126423]">Iwasaki 2011</a>). </p> <p>In an RCT, children with nonambulatory cerebral palsy were reported to benefit from treatment with pamidronate (bisphosphonate). The study reported an average 89% increase in BMD in the distal femur in children treated with intravenous bisphosphonate over a 18‐month study period, compared with a 9% increase in BMD in the placebo group (<a href="./references#CD012756-bbs2-0001" title="HendersonRC , LarkRK , KecskemethyHH , MillerF , HarckeHT , BachrachSJ . Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. Journal of Pediatrics2002;141(5):644-51. [DOI: 10.1067/mpd.2002.128207] [PMID: 12410192]">Henderson 2002</a>). </p> </section> <section id="CD012756-sec-0013"> <h3 class="title" id="CD012756-sec-0013">Why it is important to do this review</h3> <p>Osteoporosis is common in children with cerebral palsy. Around 80% to 90% of nonambulatory children with severe cerebral palsy have low BMD, and the incidence of fragility fractures is very high (<a href="./references#CD012756-bbs2-0001" title="HendersonRC , LarkRK , KecskemethyHH , MillerF , HarckeHT , BachrachSJ . Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. Journal of Pediatrics2002;141(5):644-51. [DOI: 10.1067/mpd.2002.128207] [PMID: 12410192]">Henderson 2002</a>; <a href="./references#CD012756-bbs2-0051" title="MerglerS , EvenhuisHM , BootAM , De ManSA , Bindels-De HeusKG , HuijbersWA , et al. Epidemiology of low bone mineral density and fractures in children with severe cerebral palsy: a systematic review. Developmental Medicine and Child Neurology2009;51(10):773–8. [DOI: 10.1111/j.1469-8749.2009.03384.x] [PMID: 19614941]">Mergler 2009</a>). Fractures diminish the quality of life of these children. </p> <p>Current guidelines do not support the use of anabolic therapies in children for treating osteoporosis, due to concerns related to osteosarcoma, which was identified in rats in a clinical trial setting (<a href="./references#CD012756-bbs2-0072" title="VahleJL , SatoM , LongGG , YoungJK , FrancisPC , EngelhardtJA , et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicologic Pathology2002;30(3):312-21. [DOI: 10.1080/01926230252929882] [PMID: 12051548]">Vahle 2002</a>). Thus, bisphosphonate remains the most practical, bone‐altering therapy available to children with cerebral palsy for the treatment of osteoporosis. Although bisphosphonate remains a promising treatment, there is no consensus regarding the timing, dose, or duration of treatment (<a href="./references#CD012756-bbs2-0064" title="SimmPJ , BigginA , ZacharinMR , RoddaCP , ThamE , SiafarikasA , et al. Consensus guidelines on the use of bisphosphonate therapy in children and adolescents. Journal of Paediatrics and Child Health2018;54(3):223-33. [DOI: 10.1111/jpc.13768] [PMID: 29504223]">Simm 2018</a>). Therefore, there is a need for evidence‐based guidelines and a review of studies related to bisphosphonate use in this population. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012756-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012756-sec-0014"></div> <p>To examine the efficacy and safety of bisphosphonate therapy in the treatment of low bone mineral density or secondary osteoporosis (or both) in children with cerebral palsy (Gross Motor Function Classification System Levels III to V), who are under 18 years of age. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012756-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012756-sec-0015"></div> <section id="CD012756-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012756-sec-0017"> <h4 class="title">Types of studies</h4> <p>All randomised controlled trials (RCTs) and quasi‐RCTs that implemented bisphosphonate in the treatment of low bone mineral density (BMD) or secondary osteoporosis (or both) in children and adolescents with cerebral palsy. </p> </section> <section id="CD012756-sec-0018"> <h4 class="title">Types of participants</h4> <p>Children under 18 years of age with cerebral palsy (Gross Motor Function Classification System (GMFCS) Levels III to V). </p> <p>We did not include data from studies that did not differentiate between children with osteogenesis imperfecta (OI) and idiopathic juvenile osteoporosis (IJO), and children with osteoporosis due to other conditions. </p> </section> <section id="CD012756-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Oral or intravenous (IV) administration of at least one bisphosphonate (e.g. alendronate, pamidronate, etidronate, clodronate, tiludronate, olpadronate, incadronate, risedronate, zoledronate, or a combination), given at any dose, to treat low BMD or osteoporosis in children with cerebral palsy, compared with placebo or no drug. </p> </section> <section id="CD012756-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD012756-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012756-list-0001"> <li> <p>Change in areal BMD z‐score of the lumbar spine, total body minus the head, or lateral distal femur, measured by dual X‐ray absorptiometry (DXA scan) </p> </li> <li> <p>Volumetric BMD of distal tibia or radius, using peripheral, quantitative computerised tomography (pQCT) </p> </li> <li> <p>Fracture frequency: number of incident fractures (clinical, radiographic, or both) noted per participant per year before and after bisphosphonate treatment </p> </li> <li> <p>Adverse effects associated with bisphosphonate use, experienced by the participants (which could have included acute symptoms (fever, chills, malaise); gastrointestinal symptoms, including nausea, vomiting, and abdominal pain; or possible sequelae, including hypocalcaemia, hypophosphataemia, bone pain, transient uveitis, nephrocalcinosis, acute tubular necrosis, delayed fracture healing, and death) </p> </li> </ul> </p> </section> <section id="CD012756-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012756-list-0002"> <li> <p>Changes in serum or urine bone markers, such as bone‐specific alkaline phosphatase, osteocalcin, and N‐telopeptides, before and after bisphosphonate treatment, to ascertain whether bone turnover was impacted or overly suppressed </p> </li> <li> <p>Bone pain and quality of life, as reported by the participant or the child’s parents, before and after bisphosphonate use </p> </li> </ul> </p> <p>We included studies that used any validated scale to measure the primary and secondary outcomes listed above. </p> <p>Both included studies assessed outcomes between four and six months post‐intervention.</p> <p>We included all of our outcomes in a summary of findings table.</p> </section> </section> </section> <section id="CD012756-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched the following databases, using the search strategies in <a href="./appendices#CD012756-sec-0090">Appendix 2</a>. We did not apply a study methods filter, or limit the searches by language, date, or publication status. </p> <section id="CD012756-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases and trial registers for all available years, up to September 2020. </p> <p> <ul id="CD012756-list-0003"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2020, Issue 8) in the Cochrane Library, which includes the Cochrane Developmental, Psychosocial and Learning Problems Group Specialised Register (searched 6 September 2020); </p> </li> <li> <p>MEDLINE Ovid (1946 to 6 September 2020);</p> </li> <li> <p>MEDLINE In‐Process and Other Non‐Indexed Citations Ovid (6 September 2020);</p> </li> <li> <p>MEDLINE Epub ahead of Print Ovid (6 September 2020);</p> </li> <li> <p>Embase Ovid (1974 to 2017 week 35);</p> </li> <li> <p>Embase.com Elsevier (2017 to 6 September 2020);</p> </li> <li> <p>CINAHL Plus EBSCOhost (Cumulative Index to Nursing and Allied Health Literature; 1937 to 6 September 2020); </p> </li> <li> <p><i>Cochrane Database of Systematic Reviews</i> (CDSR; 2020, Issue 8), in the Cochrane Library (searched 6 September 2020); </p> </li> <li> <p>Database of Abstracts of Reviews of Effects (DARE; 2015, Issue 2; final issue) part of the Cochrane Library (searched 30 August 2017); </p> </li> <li> <p>Epistemonikos (<a href="https://www.epistemonikos.org/" target="_blank">www.epistemonikos.org</a>; searched 6 September 2020); </p> </li> <li> <p>Science Citation Index and Social Sciences Citation Index Web of Science (SCI and SSCI; 1970 to 6 September 2020); </p> </li> <li> <p>Clinicaltrials.gov (<a href="http://clinicaltrials.gov/" target="_blank">clinicaltrials.gov</a>; searched 6 September 2020); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP; <a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch</a>; searched 6 September 2020). </p> </li> </ul> </p> </section> <section id="CD012756-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of relevant systematic reviews, trials, and case studies identified by the search. We contacted the authors of relevant studies in an attempt to identify unpublished literature. </p> </section> </section> <section id="CD012756-sec-0026"> <h3 class="title" id="CD012756-sec-0026">Data collection and analysis</h3> <p>In the following section, we report only the methods used in the review. Planned and unused methods can be found in <a href="#CD012756-tbl-0002">Table 1</a> and the review Protocol (<a href="./references#CD012756-bbs2-0075" title="ZareenZ , McDonnellC , Mc DonaldD , MolloyE . Bisphosphonate use in children with cerebral palsy. Cochrane Database of Systematic Reviews2017, Issue 8. Art. No: CD012756. [DOI: 10.1002/14651858.CD012756]">Zareen 2017</a>). </p> <div class="table" id="CD012756-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Unused methods</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Section of Protocol (</b><a href="./references#CD012756-bbs2-0075" title="ZareenZ , McDonnellC , Mc DonaldD , MolloyE . Bisphosphonate use in children with cerebral palsy. Cochrane Database of Systematic Reviews2017, Issue 8. Art. No: CD012756. [DOI: 10.1002/14651858.CD012756]"><b>Zareen 2017</b> </a><b>)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Planned approach</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Why the methods were not used</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Types of outcome measures</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We had planned to collect primary outcomes for the following time points: short‐term (zero to less than one month postintervention), intermediate‐term (one month to less than six months postintervention), and long‐term (equal to or greater than six months postintervention). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were insufficient data from the studies identified to complete this analysis.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of risk of bias in included studies</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We used the Cochrane RoB 1 tool when assessing the risk of bias in each domain for both included studies. Neither study was assessed as having an unclear risk of bias in all domains. In future updates of this review, we will apply the Cochrane RoB 2 tool in assessing the risk of bias for each domain in included studies, and apply the risk of bias due to missing evidence tool in assessing the risk of non‐reported evidence once the final version is released. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The review was conducted prior to the publication of updated guidelines on the assessment of risk of bias in included studies. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Measures of treatment effect</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dichotomous data</b> </p> <p>We had intended to calculate the effect size as a risk ratio, and present it with 95% confidence intervals (CI). We had planned to consider a change as an improvement in bone mineral density (BMD) of the femur (lateral or distal), lumbar spine, and total body minus the head, measured by dual‐Energy x‐Ray absorptiometry (DXA), or volumetric BMD, measured by peripheral, quantitative computerised tomography (pQCT). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study did not identify any relevant dichotomous data.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Continuous data</b> </p> <p>For studies that measured the same outcome using different scales, we had planned to use the standardised mean difference (SMD) with 95% CI. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies used the same measures to assess the outcomes.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Multiple outcomes</b> </p> <p>Had studies provided multiple, interchangeable measures of the same construct at the same point in time, we would have calculated the average SMD across the outcomes and the average estimated variances (<a href="./references#CD012756-bbs2-0031" title="BorensteinM , HedgesLV , HigginsJPT , RothsteinHR . Chapter 24: Multiple outcomes or time-points within a study. In: Introduction to Meta-Analysis. Chichester: John Wiley &amp; Sons, Ltd, 2009.">Borenstein 2009</a>). The aim here would have been to prevent studies that reported on more outcome measures from receiving more weight in an analysis than studies that reported on only a single outcome measure. </p> <p>The effect estimate could have been presented as a mean difference, by transforming the SMD effect estimate backwards to one of the well‐known scales, together with a pre‐defined minimal clinically important difference. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies measuring multiple outcomes were identified in this review.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Unit of analysis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cluster‐randomised trials</b> </p> <p>Had we identified cluster‐randomised trials, we would have sought direct estimates of the effect from an analysis that accounted for the cluster design. If the analysis had not accounted for the cluster design in the cluster trial, we would have used the approximately correct analysis approach, as presented in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012756-bbs2-0044" title="HigginsJPT , EldridgeS , LiT , editor(s). Chapter 23: Including variants on randomized trials. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020a</a>). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any cluster‐randomised trials in this review.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cross‐over trials</b> </p> <p>We had only planned to include cross‐over trials in the meta‐analysis when the data were clear of carry‐over effects. We would have combined the results of cross‐over studies with those of parallel studies by imputing the correlation coefficient from an included study that presented individual participant data, and used this to calculate the standard deviation (SD). We would have used the generic inverse‐variance method to conduct a meta‐analysis of this data (<a href="./references#CD012756-bbs2-0044" title="HigginsJPT , EldridgeS , LiT , editor(s). Chapter 23: Including variants on randomized trials. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020a</a>). To avoid presenting repeated measurements reported in a study, we would have only included data from one time point from an individual study in any single meta‐analysis. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any cross‐over trials in this review.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies with multiple treatment groups</b> </p> <p>Had we identified any studies with multiple treatment groups, we would have combined all relevant intervention groups and compared them with all relevant control groups, making single pair‐wise comparisons. If this approach had not allowed for investigation of intervention‐related sources of heterogeneity, we would have included each intervention arm in separate pair‐wise comparisons, halving the sample size for the control group so to avoid double counting of participants. For dichotomous outcomes, we would have added the number of participants with intervention and the total number of participants, across the groups (<a href="./references#CD012756-bbs2-0044" title="HigginsJPT , EldridgeS , LiT , editor(s). Chapter 23: Including variants on randomized trials. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020a</a>). In case of continuous outcomes, we would have combined the mean and standard deviation using the formulae described in Chapter 10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012756-bbs2-0034" title="DeeksJJ , HigginsJPT , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Deeks 2020</a>). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any studies with multiple treatment groups. All relevant studies were a direct comparison of treatment groups to placebo or standard treatment. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dealing with missing data</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If additional data had been made available, we had planned to include them in the analysis. If we received no response from the study authors, or the data were not made available, we had planned to: </p> <p> <ul id="CD012756-list-0004"> <li> <p>calculate missing summary data (such as missing SD) from CIs, standard errors, P values or t values, where possible, using the methods provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012756-bbs2-0045" title="HigginsJPT , LiT , DeeksJJ , editor(s). Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020b</a>); </p> </li> <li> <p>carry the last observation forward for missing continuous data; and</p> </li> <li> <p>in the case of missing dichotomous data, assume that all missing participants experienced the event. </p> </li> </ul> </p> <p>We also would have specified the methods used to estimate the data in the 'Characteristics of included studies' tables and performed a <a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011780/full#CD011780-sec3-0017" target="_blank">Sensitivity analysis</a> to compare the results of analyses with imputed missing data to those without imputed missing data. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It was not possible to impute missing data in the review.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of heterogeneity</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We had planned to assess statistical heterogeneity between studies by visual inspection of the forest plot for overlapping CI, using the Chi²test for homogeneity with a significance level of α (alpha) = 0.1, and calculating the I² statistic for quantifying inconsistency (estimating the percentage of variation in effect estimates due to heterogeneity rather than sampling error). We would have judged I² values based on the thresholds listed below, as suggested in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012756-bbs2-0034" title="DeeksJJ , HigginsJPT , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Deeks 2020</a>): </p> <p> <ul id="CD012756-list-0005"> <li> <p>0% and 40%: may indicate little heterogeneity;</p> </li> <li> <p>30% and 60%: may indicate moderate heterogeneity;</p> </li> <li> <p>50% and 90% may indicate substantial heterogeneity; or</p> </li> <li> <p>75% and 100% may indicate considerable heterogeneity.</p> </li> </ul> </p> <p>These thresholds can be misleading. Therefore, when considering the importance of I², we would have taken into account the size and direction of effects, and the strength of evidence for heterogeneity based on the P value from the Chi² test or a CI for I². Also, we would have estimated and presented Tau², along with its CI to provide an estimate of the amount of between‐study variation. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not assess statistical heterogeneity in this review as there were insufficient data to conduct a meta‐analysis. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of reporting bias</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Had data from a sufficient number of studies been available (at least 10 studies in a meta‐analysis), we would have drawn funnel plots and tested for funnel plot asymmetry (<a href="./references#CD012756-bbs2-0036" title="EggerM , Davey SmithG . Meta-analysis: potentials and promise. BMJ1997;315(7119):1371–4. [PMC2127866] [PMID: 9432250]">Egger 1997</a>). If we had found any asymmetry of the funnel plot, we would have looked for possible causes (such as publication bias or true heterogeneity) that we might have considered to have a likely influence on the observed effect sizes in our interpretation of the results. However, given that common tests of publication bias lack sensitivity, we would have considered the possible influence that a dominance of small trials might have had on pooled effect sizes in our interpretation, where indicated. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We could not assess reporting bias by drawing funnel plots and testing for funnel plot asymmetry due to an insufficient number of included studies. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Data synthesis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If sufficient data had been included, we would have conducted a meta‐analysis. As we would have expected some heterogeneity in intervention characteristics, we would have pooled the available data using the random‐effects model (<a href="./references#CD012756-bbs2-0034" title="DeeksJJ , HigginsJPT , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Deeks 2020</a>). However, a problem with the random‐effects model is that it assigns the same weight to all studies. Therefore, to test the robustness of our results, we would have conducted a sensitivity analysis using the fixed‐effect model. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We could not complete a meta‐analysis due to insufficient data and so provided a narrative description of the results instead. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Subgroup analysis and investigation of heterogeneity</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We had planned to perform the following subgroup analyses:</p> <p> <ul id="CD012756-list-0006"> <li> <p>dosage of bisphosphonate, since response to treatment will vary with different dosages used; </p> </li> <li> <p>duration of use, since response will vary with the duration of treatment;</p> </li> <li> <p>monotherapy (bisphosphonate only) or multiple treatment (e.g. calcium and vitamin D or alfacalcidol); </p> </li> <li> <p>participant age (e.g. preschool children (aged three to five years) versus school‐age children (aged three to 12 years)); and </p> </li> <li> <p>classification of cerebral palsy according to motor ability, as assessed using the Gross Motor Function Classification System </p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were insufficient data to conduct subgroup analyses.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity analysis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We had planned to perform a sensitivity analysis if there were sufficient data (10 or more studies). Our plan was to: </p> <p> <ul id="CD012756-list-0007"> <li> <p>explore the impact of overall risk of bias on the results, by removing the results of studies deemed to be at high or unclear (or both) risk of bias; </p> </li> <li> <p>explore the impact of missing data for our primary outcomes on the results, by comparing the results of studies with imputed data to studies with no imputed data; and </p> </li> <li> <p>assess the influence of our choice of analysis model on the results from the meta‐analysis, by re‐analysing data using a fixed‐effect model instead of a random‐effects model. </p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not perform a sensitivity analysis due to an insufficient number of included studies. </p> </td> </tr> </tbody> </table> </div> <section id="CD012756-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (TH and PS) independently checked the titles and abstracts of all records yielded by the search, and excluded those that did not meet the inclusion criteria outlined earlier. In cases that appeared to meet the inclusion criteria, or when there was any doubt as to whether the record should be excluded, both review authors retrieved the full text of the report and independently assessed it for eligibility. They resolved any disagreements by discussion, or if necessary, by consulting a third review author (EM). We recorded our decisions in a PRISMA diagram (<a href="./references#CD012756-bbs2-0052" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097] [PMC2707599] [PMID: 19621072]">Moher 2009</a>). </p> </section> <section id="CD012756-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>We used a data extraction form to ensure standardisation of the data extracted. The form was piloted by TH and PS prior to use. </p> <p>Two review authors (TH and PS) independently extracted the following data, using the standardised form developed for this purpose: </p> <p> <ul id="CD012756-list-0008"> <li> <p>study design;</p> </li> <li> <p>sample size: treatment and control groups;</p> </li> <li> <p>study population (treatment and control groups): sex, age, ambulatory, or nonambulatory cerebral palsy gross motor function (GMFCS Level), and any previous fracture; </p> </li> <li> <p>intervention: type of intervention, bisphosphonate orally or IV, dosage and duration of treatment, monotherapy or multiple treatment (e.g. calcium and vitamin D or alfacalcidol); </p> </li> <li> <p>outcome measures: improvement in BMD, fracture rate, adverse effects, changes in serum or urine bone markers, bone pain, and quality of life; </p> </li> <li> <p>potential conflicts of interest; and</p> </li> <li> <p>stated or declared conflicts of interest.</p> </li> </ul> </p> <p>Both review authors resolved disagreements regarding the extraction of data by discussion.</p> <p>We conducted the data analyses using Review Manager 5 (RevMan 5) software (<a href="./references#CD012756-bbs2-0060" title="The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. The Cochrane Collaboration, 2020.">Review Manager 2020</a>). </p> </section> <section id="CD012756-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Using Cochrane’s risk of bias tool (RoB 1 (<a href="./references#CD012756-bbs2-0042" title="HigginsJPT , AltmanDG , SterneJAC , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011a</a>)), two review authors (TH and PS) independently assessed each study for risk of bias across the following domains. </p> <p> <ul id="CD012756-list-0009"> <li> <p>Random sequence generation: was the allocation sequence adequately generated?</p> </li> <li> <p>Allocation concealment: was allocation adequately concealed?</p> </li> <li> <p>Blinding of participants and personnel: was knowledge of the allocated intervention adequately prevented during the study? </p> </li> <li> <p>Blinding of outcome assessment: was knowledge of the allocated intervention adequately prevented during the study? </p> </li> <li> <p>Incomplete outcome data: were incomplete outcome data adequately addressed?</p> </li> <li> <p>Selective reporting: are reports of the study free of suggestion of selective outcome reporting? </p> </li> <li> <p>Other sources of bias: was the study apparently free of other problems that could put it at a high risk of bias? </p> </li> </ul> </p> <p>We assigned each study a rating of high, low, or unclear (ambiguous) risk of bias for each domain; the criteria for these judgements are provided in <a href="./appendices#CD012756-sec-0104">Appendix 3</a>. We discussed any disagreements until a consensus was reached. When we rated one or more domain(s) as being at high risk of bias, we judged the study to be at high risk of bias overall. We only rated a study as being at low risk of bias overall if we rated it as such for all domains. When a study included domains rated as unclear and low risk of bias, we judged the study to be at unclear risk of bias overall. </p> <p>We present our judgements with reasons in the risk of bias tables.</p> </section> <section id="CD012756-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <section id="CD012756-sec-0031"> <h5 class="title">Continuous data</h5> <p>For continuous data, where the same continuous outcome was measured using the same scale, we presented the effect size as a mean difference (MD) with 95% confidence intervals (CIs). </p> </section> </section> <section id="CD012756-sec-0032"> <h4 class="title">Unit of analysis issues</h4> <p>We did not encounter any unit of analysis issues.</p> </section> <section id="CD012756-sec-0033"> <h4 class="title">Dealing with missing data</h4> <p>We identified and reported missing data (dropouts, withdrawals, missing summary data) in the <a href="./references#CD012756-sec-0126" title="">Characteristics of included studies</a> and risk of bias tables. </p> <p>We requested missing data from the authors of the <a href="./references#CD012756-bbs2-0002" title="IwasakiT , TakeiK , NakamuraS , HosodaN , YokotaY , IshiiM . Secondary osteoporosis in long-term bedridden patients with cerebral palsy. Pediatrics international2008;50(3):269-75. [DOI: 10.1111/j.1442-200X.2008.02571.x] [PMID: 18533934]">Iwasaki 2008</a> study, but did not receive a response. There were insufficient reported data to impute missing outcome data. We discussed this in the text, and conducted an available case analysis. We also discussed the possible impact of the missing data on the results in the discussion section. </p> </section> <section id="CD012756-sec-0034"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical and methodological heterogeneity by comparing similarities and differences in the characteristics of the participants recruited to both included studies, study designs, and methodologies, including randomisation, intervention regimens, and outcome assessments performed in both studies. We did not assess statistical heterogeneity in this review as there were insufficient data to conduct a meta‐analysis. </p> </section> <section id="CD012756-sec-0035"> <h4 class="title">Assessment of reporting biases</h4> <p>Neither study published a protocol prior to commencement of the trial. Therefore, we compared the reported measured outcomes in the methods section of each trial with the results reported. In addition, we were unable to draw funnel plots and test for funnel plot asymmetry, because there were too few included studies. </p> </section> <section id="CD012756-sec-0036"> <h4 class="title">Data synthesis</h4> <p>We entered the data into <a href="./references#CD012756-bbs2-0060" title="The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. The Cochrane Collaboration, 2020.">Review Manager 2020</a>. We could not complete a meta‐analysis due to insufficient data, and so provide a narrative description of the results instead. </p> </section> <section id="CD012756-sec-0037"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>There were insufficient data to conduct subgroup analyses, as there were too few studies (less than three) per group, and too few participants per study (the requirement for a sample size four times higher than that required for adequate power to detect an overall effect was not met). </p> </section> <section id="CD012756-sec-0038"> <h4 class="title">Sensitivity analysis</h4> <p>We did not perform a sensitivity analysis due to insufficient included studies.</p> </section> <section id="CD012756-sec-0039"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used <a href="./references#CD012756-bbs2-0039" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed 23 May 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2020. Available at gradepro.org.">GRADEpro GDT</a> to import data from <a href="./references#CD012756-bbs2-0060" title="The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. The Cochrane Collaboration, 2020.">Review Manager 2020</a> and create a summary of findings table for our main comparison: bisphosphonate versus placebo or no drug. We included all of our primary and secondary outcomes (<a href="#CD012756-sec-0020">Types of outcome measures</a>), measured at four to six months post‐intervention in this table. </p> <p>We used the GRADE approach to assess the certainty of the body of evidence (<a href="./references#CD012756-bbs2-0040" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336:924–6. [DOI: doi.org/10.1136/bmj.39489.470347.AD] [PMC2335261] [PMID: 18436948]">Guyatt 2008</a>). For each outcome, two independent review authors (TH and PS) rated the certainty of the evidence as high, moderate, low, or very low, according to the presence of the following factors: </p> <p> <ul id="CD012756-list-0010"> <li> <p>limitations in the design and implementation of the studies, suggesting high likelihood of bias; </p> </li> <li> <p>indirectness of evidence (indirect population, intervention, controls, outcomes);</p> </li> <li> <p>inconsistency of results or unexplained heterogeneity;</p> </li> <li> <p>imprecision of results (wide CIs); we downgraded once if there were fewer than 400 participants for continuous data, or fewer than 300 events for dichotomous data (<a href="./references#CD012756-bbs2-0041" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso-CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence — imprecision. Journal of Clinical Epidemiology2011;64(12):1283–93. [DOI: 10.1016/j.jclinepi.2011.01.012] [PMID: 21839614]">Guyatt 2011</a>); and </p> </li> <li> <p>high probability of publication bias.</p> </li> </ul> </p> <p>We resolved any discrepancies by discussion.</p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012756-sec-0040" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012756-sec-0040"></div> <section id="CD012756-sec-0041"> <h3 class="title">Description of studies</h3> <section id="CD012756-sec-0042"> <h4 class="title">Results of the search</h4> <p>Our original literature search identified 305 records; the top‐up search in September 2020 identified a further 109 records. Following the exclusion of duplicates, 376 records remained. We identified no further studies through a search of the grey literature, and did not identify any ongoing studies from our searches of clinical trial registers. We excluded 345 records during title and abstract screening, leaving 31 records for which we retrieved the full texts for further examination. From these, we excluded 22 studies (from 24 reports) due to ineligible study designs, and five studies (from five reports) due to ineligible populations. Of the two studies that met the eligibility criteria, one study did not provide an adequate description of the results, and our requests for further information to the study author were not returned. See <a href="#CD012756-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD012756-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD012756-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012756.pub2/media/CDSR/CD012756/image_n/nCD012756-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD012756-sec-0043"> <h4 class="title">Included studies</h4> <p>We included two studies (34 participants) in this review (<a href="./references#CD012756-bbs2-0001" title="HendersonRC , LarkRK , KecskemethyHH , MillerF , HarckeHT , BachrachSJ . Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. Journal of Pediatrics2002;141(5):644-51. [DOI: 10.1067/mpd.2002.128207] [PMID: 12410192]">Henderson 2002</a>; <a href="./references#CD012756-bbs2-0002" title="IwasakiT , TakeiK , NakamuraS , HosodaN , YokotaY , IshiiM . Secondary osteoporosis in long-term bedridden patients with cerebral palsy. Pediatrics international2008;50(3):269-75. [DOI: 10.1111/j.1442-200X.2008.02571.x] [PMID: 18533934]">Iwasaki 2008</a>). See <a href="./references#CD012756-sec-0126" title="">Characteristics of included studies</a> for details. </p> <section id="CD012756-sec-0044"> <h5 class="title">Study design</h5> <p>Both included studies were double‐blind randomised controlled trials (RCT), designed to assess the efficacy and safety of bisphosphonate use in children with cerebral palsy. One study was placebo‐controlled (<a href="./references#CD012756-bbs2-0001" title="HendersonRC , LarkRK , KecskemethyHH , MillerF , HarckeHT , BachrachSJ . Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. Journal of Pediatrics2002;141(5):644-51. [DOI: 10.1067/mpd.2002.128207] [PMID: 12410192]">Henderson 2002</a>). </p> </section> <section id="CD012756-sec-0045"> <h5 class="title">Participants</h5> <p>Both studies recruited young people with cerebral palsy, up to the age of 16 years.</p> <p><a href="./references#CD012756-bbs2-0001" title="HendersonRC , LarkRK , KecskemethyHH , MillerF , HarckeHT , BachrachSJ . Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. Journal of Pediatrics2002;141(5):644-51. [DOI: 10.1067/mpd.2002.128207] [PMID: 12410192]">Henderson 2002</a> recruited 14 nonambulatory children and adolescents with quadriplegic cerebral palsy. Participants were matched for age (range = 6 to 16 years, mean difference = 2.4 months), sex (six pairs matched, one pair unmatched), and race (13 participants were white). All participants had an age‐normalised bone mineral density (BMD) z‐score of ≤ 2.0. One pair of children withdrew from the study and were not included in the analyses. </p> <p><a href="./references#CD012756-bbs2-0002" title="IwasakiT , TakeiK , NakamuraS , HosodaN , YokotaY , IshiiM . Secondary osteoporosis in long-term bedridden patients with cerebral palsy. Pediatrics international2008;50(3):269-75. [DOI: 10.1111/j.1442-200X.2008.02571.x] [PMID: 18533934]">Iwasaki 2008</a> recruited 20 young people with cerebral palsy and secondary osteoporosis. The participants included 10 boys; the age range was 1 year to 16 years (mean = 7.6 years). </p> </section> <section id="CD012756-sec-0046"> <h5 class="title">Settings</h5> <p>Both studies were conducted in hospital environments; one in Japan and one in the USA. </p> </section> <section id="CD012756-sec-0047"> <h5 class="title">Interventions</h5> <p>Both studies assessed the efficacy of bisphosphonate treatment compared to control groups on post‐intervention changes in BMD z‐scores. </p> <p><a href="./references#CD012756-bbs2-0001" title="HendersonRC , LarkRK , KecskemethyHH , MillerF , HarckeHT , BachrachSJ . Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. Journal of Pediatrics2002;141(5):644-51. [DOI: 10.1067/mpd.2002.128207] [PMID: 12410192]">Henderson 2002</a> used pairwise randomisation to assign half of the sample to the bisphosphonate treatment group and half to the control group. Participants were recruited as pairs matched for age, sex, and race. They received intravenous pamidronate, a second generation bisphosphonate, daily for three consecutive days. This three‐day dosing session was repeated at three‐month intervals for one year (five dosing sessions, 15 total doses); they were assessed at six months post‐intervention. Each daily dose was 1 mg pamidronate/kg body weight, but not &lt; 15 mg or &gt; 30 mg. Participants in the intervention group also received vitamin D supplementation. </p> <p><a href="./references#CD012756-bbs2-0002" title="IwasakiT , TakeiK , NakamuraS , HosodaN , YokotaY , IshiiM . Secondary osteoporosis in long-term bedridden patients with cerebral palsy. Pediatrics international2008;50(3):269-75. [DOI: 10.1111/j.1442-200X.2008.02571.x] [PMID: 18533934]">Iwasaki 2008</a> specified the use of oral risedronate, a third generation bisphosphonate. The drug was given to one group of participants for six months; they were assessed at four months post‐intervention; no further details regarding dosage, or frequency or method of administration were provided. All participants in the treatment group were also treated with alfacalcidol (reported as alfacarcidol but understood internationally as alfacalcidol) during the trial. </p> </section> <section id="CD012756-sec-0048"> <h5 class="title">Controls/Comparators</h5> <p><a href="./references#CD012756-bbs2-0001" title="HendersonRC , LarkRK , KecskemethyHH , MillerF , HarckeHT , BachrachSJ . Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. Journal of Pediatrics2002;141(5):644-51. [DOI: 10.1067/mpd.2002.128207] [PMID: 12410192]">Henderson 2002</a> compared bisphosphonate efficacy to placebo treatment. All participants in the study, regardless of treatment group, were treated with a daily supplement over the 18‐month study period. The supplement contained 1000 mg of calcium (10 mL calcium carbonate), a paediatric multivitamin, and additional vitamin D (400 IU of calciferol). </p> <p><a href="./references#CD012756-bbs2-0002" title="IwasakiT , TakeiK , NakamuraS , HosodaN , YokotaY , IshiiM . Secondary osteoporosis in long-term bedridden patients with cerebral palsy. Pediatrics international2008;50(3):269-75. [DOI: 10.1111/j.1442-200X.2008.02571.x] [PMID: 18533934]">Iwasaki 2008</a> compared the outcomes of participants treated with risedronate (plus alfacalcidol) to participants with no treatment (alfacalcidol alone). </p> </section> <section id="CD012756-sec-0049"> <h5 class="title">Outcomes</h5> <section id="CD012756-sec-0050"> <h6 class="title">Primary outcomes</h6> <p>One of the studies measured and reported the primary outcome (post‐intervention change in BMD z‐score of the lumbar spine, total body minus the head, or lateral distal femur (<a href="./references#CD012756-bbs2-0001" title="HendersonRC , LarkRK , KecskemethyHH , MillerF , HarckeHT , BachrachSJ . Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. Journal of Pediatrics2002;141(5):644-51. [DOI: 10.1067/mpd.2002.128207] [PMID: 12410192]">Henderson 2002</a>)). Post‐intervention BMD z‐scores were measured at six months following completion of the intervention. <a href="./references#CD012756-bbs2-0002" title="IwasakiT , TakeiK , NakamuraS , HosodaN , YokotaY , IshiiM . Secondary osteoporosis in long-term bedridden patients with cerebral palsy. Pediatrics international2008;50(3):269-75. [DOI: 10.1111/j.1442-200X.2008.02571.x] [PMID: 18533934]">Iwasaki 2008</a> measured the primary outcome and presented results graphically; however, they only reported the results of significant tests of between‐groups differences in change in BMD, without any measure of the effect size. Therefore, we could not include the results in a quantitative analysis. </p> <p>Neither study reported changes in fracture frequency or improvement in volumetric BMD of distal tibia or radius, using peripheral, quantitative computerised tomography (pQCT) following intervention completion. </p> <p><a href="./references#CD012756-bbs2-0001" title="HendersonRC , LarkRK , KecskemethyHH , MillerF , HarckeHT , BachrachSJ . Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. Journal of Pediatrics2002;141(5):644-51. [DOI: 10.1067/mpd.2002.128207] [PMID: 12410192]">Henderson 2002</a> also reported febrile response in participants treated with bisphosphonate, but no other adverse effects were noted. </p> </section> <section id="CD012756-sec-0051"> <h6 class="title">Secondary outcomes</h6> <p>Both studies measured and reported post‐intervention changes in serum bone markers, bone‐specific alkaline phosphatase, and N‐telopeptides. </p> <p>Neither study reported outcomes for changes in bone pain or quality of life following intervention completion. </p> </section> </section> <section id="CD012756-sec-0052"> <h5 class="title">Funding</h5> <p>The <a href="./references#CD012756-bbs2-0001" title="HendersonRC , LarkRK , KecskemethyHH , MillerF , HarckeHT , BachrachSJ . Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. Journal of Pediatrics2002;141(5):644-51. [DOI: 10.1067/mpd.2002.128207] [PMID: 12410192]">Henderson 2002</a> study was supported by Roxane Laboratories Inc, Meade Johnson, and Schwarz Pharma, which donated the various components of the calcium plus vitamin supplement; however, there was no discussion of support or supply of bisphosphonate therapy. The trial was also supported by a grant from the United Cerebral Palsy Research and Educational Foundation; at the University of North Carolina, by the General Clinical Research Centers program of the Division of Research Resources; National Institutes of Health (grant RR00046); a career award from the National Institute of Arthritis, Musculoskeletal, and Skin Diseases (AR02132); and the duPont Hospital for Children by the Nemours Foundation (W20‐8930). </p> <p><a href="./references#CD012756-bbs2-0002" title="IwasakiT , TakeiK , NakamuraS , HosodaN , YokotaY , IshiiM . Secondary osteoporosis in long-term bedridden patients with cerebral palsy. Pediatrics international2008;50(3):269-75. [DOI: 10.1111/j.1442-200X.2008.02571.x] [PMID: 18533934]">Iwasaki 2008</a> did not state the source of funding for their trial. </p> </section> </section> <section id="CD012756-sec-0053"> <h4 class="title">Excluded studies</h4> <p>We excluded 27 studies (29 full‐text reports); for details, see the <a href="./references#CD012756-sec-0127" title="">Characteristics of excluded studies</a> tables. We excluded 22 studies due to ineligible study designs for this review, and five RCTs due to ineligible populations. </p> </section> </section> <section id="CD012756-sec-0054"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed the risk of bias in both studies using the Cochrane RoB 1 tool (<a href="./references#CD012756-bbs2-0042" title="HigginsJPT , AltmanDG , SterneJAC , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011a</a>; <a href="./references#CD012756-bbs2-0043" title="HigginsJPT , AltmanDG , GøtzschePC , JüniP , MoherD , OxmanAD , et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ2011;343:d5928. [DOI: 10.1136/bmj.d5928] [PMC3196245] [PMID: 22008217]">Higgins 2011b</a>). We judged one study to have an overall high risk of bias, due to significant differences in baseline demographics between the groups without further exploration of this issue, and insufficient information reported to allow us to complete a full assessment of the methodology used, leading us to judge some elements as unclear risk of bias, and others as high risk of bias (<a href="./references#CD012756-bbs2-0002" title="IwasakiT , TakeiK , NakamuraS , HosodaN , YokotaY , IshiiM . Secondary osteoporosis in long-term bedridden patients with cerebral palsy. Pediatrics international2008;50(3):269-75. [DOI: 10.1111/j.1442-200X.2008.02571.x] [PMID: 18533934]">Iwasaki 2008</a>). The second study included several domains that we judged as unclear risk of bias, due to insufficient details reported about the study methodology; overall, we judged the study to have an unclear risk of bias <a href="./references#CD012756-bbs2-0001" title="HendersonRC , LarkRK , KecskemethyHH , MillerF , HarckeHT , BachrachSJ . Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. Journal of Pediatrics2002;141(5):644-51. [DOI: 10.1067/mpd.2002.128207] [PMID: 12410192]">Henderson 2002</a>. </p> <p>We summarise our judgements below, and graphically in <a href="#CD012756-fig-0002">Figure 2</a> and <a href="#CD012756-fig-0003">Figure 3</a>. A full account of our assessment can be found in the risk of bias tables, included with the <a href="./references#CD012756-sec-0126" title="">Characteristics of included studies</a> tables. </p> <div class="figure" id="CD012756-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD012756-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012756.pub2/media/CDSR/CD012756/image_n/nCD012756-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <div class="figure" id="CD012756-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD012756-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012756.pub2/media/CDSR/CD012756/image_n/nCD012756-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <section id="CD012756-sec-0055"> <h4 class="title">Allocation</h4> <section id="CD012756-sec-0056"> <h5 class="title">Sequence generation</h5> <p>We rated <a href="./references#CD012756-bbs2-0001" title="HendersonRC , LarkRK , KecskemethyHH , MillerF , HarckeHT , BachrachSJ . Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. Journal of Pediatrics2002;141(5):644-51. [DOI: 10.1067/mpd.2002.128207] [PMID: 12410192]">Henderson 2002</a> at unclear risk of bias as there was insufficient detail provided regarding the randomisation process. We judged <a href="./references#CD012756-bbs2-0002" title="IwasakiT , TakeiK , NakamuraS , HosodaN , YokotaY , IshiiM . Secondary osteoporosis in long-term bedridden patients with cerebral palsy. Pediatrics international2008;50(3):269-75. [DOI: 10.1111/j.1442-200X.2008.02571.x] [PMID: 18533934]">Iwasaki 2008</a> at high risk of bias due to inadequate discussion of the methodology used, and significant pre‐treatment differences in the primary outcome measure (BMD), with no further exploration of these differences. </p> </section> <section id="CD012756-sec-0057"> <h5 class="title">Allocation concealment</h5> <p>We rated both studies at unclear risk of bias, as neither study provided adequate detail to fully assess the procedures used to maintain concealment of the allocation group from study personnel. </p> </section> </section> <section id="CD012756-sec-0058"> <h4 class="title">Blinding</h4> <section id="CD012756-sec-0059"> <h5 class="title">Blinding of participants and personnel</h5> <p>We rated both studies at unclear risk of performance bias, as neither study provided adequate detail to fully assess the procedures used for blinding participants and personnel. </p> </section> <section id="CD012756-sec-0060"> <h5 class="title">Blinding of outcome assessment</h5> <p>We rated both studies as unclear risk of detection bias, as neither study provided adequate detail to fully assess the procedures used for blinding outcome assessors. </p> </section> </section> <section id="CD012756-sec-0061"> <h4 class="title">Incomplete outcome data</h4> <p>We rated both studies at low risk of attrition bias, as there were low attrition rates in both studies. In the <a href="./references#CD012756-bbs2-0001" title="HendersonRC , LarkRK , KecskemethyHH , MillerF , HarckeHT , BachrachSJ . Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. Journal of Pediatrics2002;141(5):644-51. [DOI: 10.1067/mpd.2002.128207] [PMID: 12410192]">Henderson 2002</a> study, one of seven pairs of participants withdrew from the study. Both participants in the pair withdrew, the groups were matched, and the reason for withdrawal, participant time commitment, was explained in the study. Results were available for all participants in the <a href="./references#CD012756-bbs2-0002" title="IwasakiT , TakeiK , NakamuraS , HosodaN , YokotaY , IshiiM . Secondary osteoporosis in long-term bedridden patients with cerebral palsy. Pediatrics international2008;50(3):269-75. [DOI: 10.1111/j.1442-200X.2008.02571.x] [PMID: 18533934]">Iwasaki 2008</a> study. </p> </section> <section id="CD012756-sec-0062"> <h4 class="title">Selective reporting</h4> <p>We could not assess a priori methods as there were no available published protocols. Nonetheless, we rated both studies at low risk of reporting bias, as both studies appeared to have reported on all outcomes stated in the methods sections of the reports. </p> </section> <section id="CD012756-sec-0063"> <h4 class="title">Other potential sources of bias</h4> <p>We did not identify any other sources of potential bias in either study, and so we rated both at low risk of other bias. </p> </section> </section> <section id="CD012756-sec-0064"> <h3 class="title" id="CD012756-sec-0064">Effects of interventions</h3> <p>See: <a href="./full#CD012756-tbl-0001"><b>Summary of findings 1</b> Bisphosphonate treatment (oral or intravenous) compared to placebo or no treatment for children under the age of 18 with cerebral palsy (GMFCS levels III to V)</a> </p> <p>See <a href="./full#CD012756-tbl-0001">summary of findings Table 1</a>. </p> <p>Unfortunately, as the two studies identified did not report results in sufficient detail and in a similar manner, we were unable to combine the results in a meta‐analysis; therefore, we can only report the individual study results. </p> <section id="CD012756-sec-0065"> <h4 class="title">Bisphosphonate treatment (oral or intravenous) versus placebo or no treatment</h4> <section id="CD012756-sec-0066"> <h5 class="title">Primary outcomes</h5> <section id="CD012756-sec-0067"> <h6 class="title">Change in BMD z‐score of the lumbar spine, total body minus the head, or lateral distal femur </h6> <p>Both studies measured the post‐intervention change in BMD z‐score: <a href="./references#CD012756-bbs2-0001" title="HendersonRC , LarkRK , KecskemethyHH , MillerF , HarckeHT , BachrachSJ . Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. Journal of Pediatrics2002;141(5):644-51. [DOI: 10.1067/mpd.2002.128207] [PMID: 12410192]">Henderson 2002</a> at six months, and <a href="./references#CD012756-bbs2-0002" title="IwasakiT , TakeiK , NakamuraS , HosodaN , YokotaY , IshiiM . Secondary osteoporosis in long-term bedridden patients with cerebral palsy. Pediatrics international2008;50(3):269-75. [DOI: 10.1111/j.1442-200X.2008.02571.x] [PMID: 18533934]">Iwasaki 2008</a> at four months. </p> <p><a href="./references#CD012756-bbs2-0001" title="HendersonRC , LarkRK , KecskemethyHH , MillerF , HarckeHT , BachrachSJ . Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. Journal of Pediatrics2002;141(5):644-51. [DOI: 10.1067/mpd.2002.128207] [PMID: 12410192]">Henderson 2002</a> measured BMD z‐score in multiple anatomical locations in participants treated with bisphosphonate (N = 6), and in participants in the placebo group (N = 6). Compared to participants in the placebo group, those treated with bisphosphonate had a improved BMD z‐score in the lumbar spine (MD 18%, 95% CI 13.33 to 22.67; very low certainty evidence; <a href="./references#CD012756-fig-0004" title="">Analysis 1.1</a>); metaphysis of the distal femur just proximal to the growth plate (region one; MD 80%, 95% CI 62.52 to 97.48; very low certainty evidence; <a href="./references#CD012756-fig-0005" title="">Analysis 1.2</a>); region of transition between the broad metaphysis of the distal femur and the narrow femoral shaft (region two; MD 27%, 95% CI 19.62 to 34.38; very low certainty evidence; <a href="./references#CD012756-fig-0006" title="">Analysis 1.3</a>); and distal portion of the femoral diaphysis (region three; MD 12%, 95% CI 6.34 to 17.66; very low certainty evidence; <a href="./references#CD012756-fig-0007" title="">Analysis 1.4</a>). </p> <p><a href="./references#CD012756-bbs2-0002" title="IwasakiT , TakeiK , NakamuraS , HosodaN , YokotaY , IshiiM . Secondary osteoporosis in long-term bedridden patients with cerebral palsy. Pediatrics international2008;50(3):269-75. [DOI: 10.1111/j.1442-200X.2008.02571.x] [PMID: 18533934]">Iwasaki 2008</a> measured changes in BMD between participants in the bisphosphonate group (N = 10; risedronate plus alfacalcidol), and participants in the no treatment group (N = 10; alfacalcidol alone). The study authors only provided results for significance tests, so we could not assess the magnitude of the effect size. They reported that treatment improved post‐intervention BMD in both groups (alfacalcidol alone: P = 0.003; bisphosphonate plus alfacalcidol: P = 0.003). However, the two groups are not comparable since the BMD was not similar at baseline between groups (P = 0.008). Accepting this limitation of the study, the results suggest that bisphosphonate plus alfacalcidol might improve BMD more than alfacalcidol alone (P = 0.02). </p> <p>While both trials found that bisphosphonate treatment lead to a better improvement in BMD z‐scores in participants with cerebral palsy, we could not estimate the size of the pooled effect due to differences in reporting methods. We contacted the authors of the <a href="./references#CD012756-bbs2-0002" title="IwasakiT , TakeiK , NakamuraS , HosodaN , YokotaY , IshiiM . Secondary osteoporosis in long-term bedridden patients with cerebral palsy. Pediatrics international2008;50(3):269-75. [DOI: 10.1111/j.1442-200X.2008.02571.x] [PMID: 18533934]">Iwasaki 2008</a> study for further statistical details, but did not receive a response. </p> </section> <section id="CD012756-sec-0068"> <h6 class="title">Volumetric BMD</h6> <p>Neither study reported data on differences in changes in volumetric BMD following treatment intervention. </p> </section> <section id="CD012756-sec-0069"> <h6 class="title">Fracture frequency</h6> <p>Neither study reported data on differences in changes in fracture frequency following treatment intervention. </p> </section> <section id="CD012756-sec-0070"> <h6 class="title">Adverse effects</h6> <p><a href="./references#CD012756-bbs2-0001" title="HendersonRC , LarkRK , KecskemethyHH , MillerF , HarckeHT , BachrachSJ . Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. Journal of Pediatrics2002;141(5):644-51. [DOI: 10.1067/mpd.2002.128207] [PMID: 12410192]">Henderson 2002</a> reported consistently elevated axillary temperature (&gt; 37 °C) in two of six participants receiving their first three‐day pamidronate dosing session, but not during any subsequent dosing session. Participants receiving placebo treatment recorded no elevation in body temperature during the first dosing session, but was noted in four subsequent sessions. No differences in white blood cell count were noted between treatment groups. No other adverse events were reported. </p> <p><a href="./references#CD012756-bbs2-0002" title="IwasakiT , TakeiK , NakamuraS , HosodaN , YokotaY , IshiiM . Secondary osteoporosis in long-term bedridden patients with cerebral palsy. Pediatrics international2008;50(3):269-75. [DOI: 10.1111/j.1442-200X.2008.02571.x] [PMID: 18533934]">Iwasaki 2008</a> did not report adverse events. </p> </section> </section> <section id="CD012756-sec-0071"> <h5 class="title">Secondary outcomes</h5> <section id="CD012756-sec-0072"> <h6 class="title">Changes in serum or urine bone markers</h6> <p>Both studies measured post‐intervention changes in serum bone markers.</p> <section id="CD012756-sec-0073"> <p><b>N‐telopeptides (NTX)</b></p> <p><a href="./references#CD012756-bbs2-0001" title="HendersonRC , LarkRK , KecskemethyHH , MillerF , HarckeHT , BachrachSJ . Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. Journal of Pediatrics2002;141(5):644-51. [DOI: 10.1067/mpd.2002.128207] [PMID: 12410192]">Henderson 2002</a> reported serum results graphically and descriptively but did not provide a numerical summary. </p> <p><a href="./references#CD012756-bbs2-0002" title="IwasakiT , TakeiK , NakamuraS , HosodaN , YokotaY , IshiiM . Secondary osteoporosis in long-term bedridden patients with cerebral palsy. Pediatrics international2008;50(3):269-75. [DOI: 10.1111/j.1442-200X.2008.02571.x] [PMID: 18533934]">Iwasaki 2008</a> measured pre‐ and post‐intervention NTX levels and reported significant correlations between pre‐ and post‐intervention NTX/Creatinine levels in both the bisphosphonate (r = 0.89, P &lt; 0.001) and no treatment groups (r = 0.69, P = 0.003). There was no discussion or presentation of differences in post‐intervention changes in NTX alone, or in differences between groups. However, <a href="./references#CD012756-bbs2-0002" title="IwasakiT , TakeiK , NakamuraS , HosodaN , YokotaY , IshiiM . Secondary osteoporosis in long-term bedridden patients with cerebral palsy. Pediatrics international2008;50(3):269-75. [DOI: 10.1111/j.1442-200X.2008.02571.x] [PMID: 18533934]">Iwasaki 2008</a> reported there was no significant correlation between the post‐intervention change in NTX and the post‐intervention change in BMD. </p> </section> <section id="CD012756-sec-0074"> <p><b>Bone‐specific alkaline phosphatase (BAP)</b></p> <p><a href="./references#CD012756-bbs2-0001" title="HendersonRC , LarkRK , KecskemethyHH , MillerF , HarckeHT , BachrachSJ . Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. Journal of Pediatrics2002;141(5):644-51. [DOI: 10.1067/mpd.2002.128207] [PMID: 12410192]">Henderson 2002</a> reported no post‐intervention changes in BAP following treatment with pamidronate. There was no further discussion or presentation of results. </p> <p><a href="./references#CD012756-bbs2-0002" title="IwasakiT , TakeiK , NakamuraS , HosodaN , YokotaY , IshiiM . Secondary osteoporosis in long-term bedridden patients with cerebral palsy. Pediatrics international2008;50(3):269-75. [DOI: 10.1111/j.1442-200X.2008.02571.x] [PMID: 18533934]">Iwasaki 2008</a> reported a post‐intervention reduction in BAP levels in both groups. They reported significant correlations between the pre‐ and post‐intervention BAP levels for both the bisphosphonate (r = 0.89, P = 0.02) and the no treatment groups (r = 0.72, P = &lt; 0.001). There was no discussion or presentation of differences in post‐intervention changes in BAP between groups. </p> </section> <section id="CD012756-sec-0075"> <p><b>Osteocalcin</b></p> <p><a href="./references#CD012756-bbs2-0001" title="HendersonRC , LarkRK , KecskemethyHH , MillerF , HarckeHT , BachrachSJ . Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. Journal of Pediatrics2002;141(5):644-51. [DOI: 10.1067/mpd.2002.128207] [PMID: 12410192]">Henderson 2002</a> reported no post‐intervention change in osteocalcin following treatment with pamidronate. There was no further discussion or presentation of results. </p> <p><a href="./references#CD012756-bbs2-0002" title="IwasakiT , TakeiK , NakamuraS , HosodaN , YokotaY , IshiiM . Secondary osteoporosis in long-term bedridden patients with cerebral palsy. Pediatrics international2008;50(3):269-75. [DOI: 10.1111/j.1442-200X.2008.02571.x] [PMID: 18533934]">Iwasaki 2008</a> did not report measurement or outcomes for osteocalcin. </p> </section> </section> <section id="CD012756-sec-0076"> <h6 class="title">Bone pain and quality of Life</h6> <p>Neither study reported data on either bone pain or quality of life following treatment.</p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012756-sec-0077" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012756-sec-0077"></div> <section id="CD012756-sec-0078"> <h3 class="title" id="CD012756-sec-0078">Summary of main results</h3> <p>We evaluated the evidence for bisphosphonate treatment to improve bone health in children with cerebral palsy and low bone mineral density (BMD) or osteoporosis. </p> <p>We included two small studies (N = 34) that compared the effect of bisphosphonate treatment to control on bone health in children with cerebral palsy, under 16 years of age. Neither study reported data on changes in volumetric BMD, fracture frequency, bone pain, or quality of life. We were not able to combine the data from the studies in a meta‐analysis, due to differences in reporting methods. </p> <p>There was very low certainty evidence from one study that, compared to placebo, bisphosphonate treatment improved BMD z‐scores at six months post‐intervention in the lumbar spine, in femur region one (metaphysis just proximal to the growth plate), and femur region two (region of transition between the broad metaphysis and narrow femoral shaft), but not in femur region three (distal portion of the femoral diaphysis). </p> <p>The other study reported changes descriptively and graphically for BMD at four months post‐intervention for children treated with bisphosphonates and vitamin D (bisphosphonate group) compared to those treated with vitamin D alone (no treatment group). They described an improvement in BMD in both groups, with more improvement in the bisphosphonate group. </p> <p>One study described febrile events in two children receiving bisphosphonates during their first dosing session, and subsequently on four occasions amongst children receiving placebo treatment. They did not note any differences in white blood cell counts or any other adverse events. </p> <p>One study reported that bisphosphonate reduced serum N‐telopeptides (NTX) more than placebo, but the results were inconclusive between groups for bone‐specific alkaline phosphatase (BAP). The other study reported a reduction in NTX and BAP in both the bisphosphonate and no treatment groups, but did not compare the difference between groups. </p> </section> <section id="CD012756-sec-0079"> <h3 class="title" id="CD012756-sec-0079">Overall completeness and applicability of evidence</h3> <p>We included two small studies, with a total sample size of 34 participants that reported the effect of bisphosphonate treatment on post‐intervention changes in BMD. We were unable to combine results because of differences in comparators and unavailability of usable data. </p> <p>Both studies were carried out over 10 years ago, and we identified no further completed studies of bisphosphonate treatment in children with cerebral palsy since then. In recent years, several other therapies to improve BMD in children with cerebral palsy have been investigated, including weight‐bearing activities and vitamin D supplementation, with or without calcium. The effect of bisphosphonate must now be assessed in the context of recent evidence of other interventions to improve osteoporosis and low BMD in children with cerebral palsy. </p> <p>Both studies were completed in high‐resource countries (USA and Japan). The availability of complementary therapies and variation in treatments for children with cerebral palsy is likely to be different in low‐resource countries. This limits the generalisability of the results of this review to low‐resource settings. </p> <p>While low BMD is an important risk factor for fractures in this population, neither study measured fracture frequency, bone pain, or quality of life. These are measures that are of great significance to children in this population, and limits the value of the results of the included studies. </p> <p>We conclude that there is very low certainty evidence to suggest bisphosphonate treatment may improve BMD in children with cerebral palsy; however, we cannot estimate the size of this effect nor the impact this change in BMD may have on fracture frequency, bone pain, or quality of life in this group of children. </p> </section> <section id="CD012756-sec-0080"> <h3 class="title" id="CD012756-sec-0080">Quality of the evidence</h3> <p>The overall certainty of the evidence from this study is very low for each outcome presented in <a href="./full#CD012756-tbl-0001">summary of findings Table 1</a>. We identified only two studies, both with small participant numbers; one of which was at overall high risk of bias, and one at unclear risk of bias due to insufficient data reported. </p> <p>We applied the GRADE approach to assess the certainty of the evidence for this review. We downgraded the certainty of evidence by three levels for two reasons: 1) downgraded by two levels due to study limitations, as we considered there to be substantial risk of bias; one study was at high risk of bias and one study was at unclear risk of bias and 2) downgraded by one level as it was not possible to assess the pooled effect size of the two studies due to reporting differences and very serious imprecision, with very wide confidence intervals reflecting the small sample sizes; in some cases, the evidence was based only on one RCT of 12 participants. </p> </section> <section id="CD012756-sec-0081"> <h3 class="title" id="CD012756-sec-0081">Potential biases in the review process</h3> <p>For this review, we followed the criteria and methodology outlined in the <a href="#CD012756-sec-0015">Methods</a> section, in which we adhered to standard methodological procedures expected by Cochrane. We minimised risk of bias in the review by employing two independent authors to screen records and reports, extract data, and assess the certainty of the evidence from all studies identified by the search and deemed relevant for inclusion. The search strategy is outlined in <a href="./appendices#CD012756-sec-0090">Appendix 2</a>; no restrictions by language or publication type were applied. The number of records yielded by the search strategy was low, so we made significant efforts to identify other relevant studies through discussion with key experts and by conducting searches of the grey literature. We did not identify any additional studies eligible for inclusion and other, recent systematic reviews have not included any other studies suitable for our review. However, the possibility remains that there may be relevant unpublished studies that we have not included in this review, although we believe the overall risk of publication bias is small. </p> </section> <section id="CD012756-sec-0082"> <h3 class="title" id="CD012756-sec-0082">Agreements and disagreements with other studies or reviews</h3> <p>We identified three other systematic reviews (<a href="./references#CD012756-bbs2-0037" title="FehlingsD , SwitzerL , AgarwalP , WongC , SorchettE , StevensonR , et al. Informing evidence-based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis: a systematic review. Developmental Medicine and Child Neurology2012;54(2):106-16. [DOI: 10.1111/j.1469-8749.2011.04091.x] [PMID: 22111966]">Fehlings 2012</a>; <a href="./references#CD012756-bbs2-0049" title="KimMJ , KimSN , LeeIS , ChungS , LeeJ , YangY , et al. Effects of bisphosphonates to treat osteoporosis in children with cerebral palsy: a meta-analysis. Journal of Pediatric Endocrinology and Metabolism2015;28(11-12):1343-50. [DOI: 10.1515/jpem-2014-0527] [PMID: 26214607]">Kim 2015</a>; <a href="./references#CD012756-bbs2-0055" title="OzelS , SwitzerL , MacintoshA , FehlingsD . Informing evidence-based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis: an update. Developmental Medicine and Child Neurology2016;58(9):918-23. [DOI: 10.1111/dmcn.13196] [PMID: 27435427]">Ozel 2016</a>), and one recent consensus guideline (<a href="./references#CD012756-bbs2-0064" title="SimmPJ , BigginA , ZacharinMR , RoddaCP , ThamE , SiafarikasA , et al. Consensus guidelines on the use of bisphosphonate therapy in children and adolescents. Journal of Paediatrics and Child Health2018;54(3):223-33. [DOI: 10.1111/jpc.13768] [PMID: 29504223]">Simm 2018</a>), on the use of bisphosphonate and other treatments for low BMD or secondary osteoporosis in children with cerebral palsy. All of these studies included lower levels of evidence from uncontrolled trials and observational studies. No study reported outcomes outside of this review; however, all the reviews also considered other treatments to improve BMD in children with cerebral palsy. All studies were consistent in their support for the use of bisphosphonate therapy in children under 18 years old with cerebral palsy and low BMD or osteoporosis. </p> <p><a href="./references#CD012756-bbs2-0037" title="FehlingsD , SwitzerL , AgarwalP , WongC , SorchettE , StevensonR , et al. Informing evidence-based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis: a systematic review. Developmental Medicine and Child Neurology2012;54(2):106-16. [DOI: 10.1111/j.1469-8749.2011.04091.x] [PMID: 22111966]">Fehlings 2012</a> published a systematic review of interventions for children with cerebral palsy and low BMD. They included studies with at least 10 children under the age of 18 years with cerebral palsy and low BMD. They restricted the review to English language studies only. The review included five studies of bisphosphonates, four of intravenous pamidronate and one of oral risedronate, and all included children were non‐ambulatory (GMFCS Level IV or V). The authors included both the <a href="./references#CD012756-bbs2-0001" title="HendersonRC , LarkRK , KecskemethyHH , MillerF , HarckeHT , BachrachSJ . Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. Journal of Pediatrics2002;141(5):644-51. [DOI: 10.1067/mpd.2002.128207] [PMID: 12410192]">Henderson 2002</a> and <a href="./references#CD012756-bbs2-0002" title="IwasakiT , TakeiK , NakamuraS , HosodaN , YokotaY , IshiiM . Secondary osteoporosis in long-term bedridden patients with cerebral palsy. Pediatrics international2008;50(3):269-75. [DOI: 10.1111/j.1442-200X.2008.02571.x] [PMID: 18533934]">Iwasaki 2008</a> studies in their analysis, along with two uncontrolled clinical trials and one retrospective cohort study. Four studies supported the use of bisphosphonate therapy for increasing BMD in this population. The authors concluded that overall, there was evidence of probable effectiveness (American Academy of Neurology classification level B) that bisphosphonate increases BMD in children with cerebral palsy. Two of the studies included in the review reported that bisphosphonate treatment reduced fragility fractures in children with cerebral palsy. They concluded that there was evidence of possible effectiveness (level C) to support the use of bisphosphonate to reduce the incidence of fragility fractures in children with cerebral palsy. They also noted adverse events reported by the studies, which included fever, flu‐like symptoms, and hypocalcaemia. </p> <p><a href="./references#CD012756-bbs2-0055" title="OzelS , SwitzerL , MacintoshA , FehlingsD . Informing evidence-based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis: an update. Developmental Medicine and Child Neurology2016;58(9):918-23. [DOI: 10.1111/dmcn.13196] [PMID: 27435427]">Ozel 2016</a> published an update to <a href="./references#CD012756-bbs2-0037" title="FehlingsD , SwitzerL , AgarwalP , WongC , SorchettE , StevensonR , et al. Informing evidence-based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis: a systematic review. Developmental Medicine and Child Neurology2012;54(2):106-16. [DOI: 10.1111/j.1469-8749.2011.04091.x] [PMID: 22111966]">Fehlings 2012</a>. They included studies of children under the age of 18 years with cerebral palsy and low BMD from January 2010 to March 2016. The updated review included one uncontrolled study and two retrospective cohort studies. Two studies supported the use of bisphosphonate to increase BMD in children with cerebral palsy; however, there was insufficient new evidence to upgrade the classification of evidence from level B (probable effectiveness). Two studies reported a reduction in fracture rate with the use of bisphosphonate therapy; however, there was insufficient new evidence to upgrade the classification from level C (possible effectiveness). </p> <p><a href="./references#CD012756-bbs2-0049" title="KimMJ , KimSN , LeeIS , ChungS , LeeJ , YangY , et al. Effects of bisphosphonates to treat osteoporosis in children with cerebral palsy: a meta-analysis. Journal of Pediatric Endocrinology and Metabolism2015;28(11-12):1343-50. [DOI: 10.1515/jpem-2014-0527] [PMID: 26214607]">Kim 2015</a> completed a systematic review of bisphosphonate to treat osteoporosis in children with cerebral palsy. They included studies published in English, up to April 2014, of bisphosphonates in children under 18 years old with cerebral palsy and osteoporosis (BMD z‐score ≤ 2.0) that reported outcomes for changes in BMD z‐score. The review included four studies: <a href="./references#CD012756-bbs2-0001" title="HendersonRC , LarkRK , KecskemethyHH , MillerF , HarckeHT , BachrachSJ . Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. Journal of Pediatrics2002;141(5):644-51. [DOI: 10.1067/mpd.2002.128207] [PMID: 12410192]">Henderson 2002</a>, and three uncontrolled trials. They found that bisphosphonate treatment improved lumbar spine BMD (standardised mean difference (SMD) 0.799, 95% CI 0.499 to 1.100), and femoral BMD (SMD 0.748, 95% CI 0.382 to 1.114). </p> <p>The <a href="./references#CD012756-bbs2-0064" title="SimmPJ , BigginA , ZacharinMR , RoddaCP , ThamE , SiafarikasA , et al. Consensus guidelines on the use of bisphosphonate therapy in children and adolescents. Journal of Paediatrics and Child Health2018;54(3):223-33. [DOI: 10.1111/jpc.13768] [PMID: 29504223]">Simm 2018</a> consensus guideline on the use of bisphosphonate in children and adolescents, was published on behalf of the Australasian Pediatric Endocrine Group. It was based on the available evidence of bisphosphonates, along with other treatment options for low BMD. The authors noted that there was evidence that bisphosphonates increased BMD in people with cerebral palsy and low BMD, and highlighted the findings by <a href="./references#CD012756-bbs2-0055" title="OzelS , SwitzerL , MacintoshA , FehlingsD . Informing evidence-based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis: an update. Developmental Medicine and Child Neurology2016;58(9):918-23. [DOI: 10.1111/dmcn.13196] [PMID: 27435427]">Ozel 2016</a>. They also noted the paucity of RCTs to provide conclusive evidence, and the lack of evidence regarding the effect of bisphosphonate therapy on fracture risk. They recommended yearly BMD measurement with bisphosphonate treatment lasting for longer than two years only when there was ongoing fracture risk or bone pain, and concluded that the area is in need of further research. </p> <p>We also identified one additional, relevant placebo‐controlled RCT established in France, which was registered with clinicaltrials.gov; however, it was terminated after having recruited only two participants. No explanation for the termination of the trial is provided and there has been no update since 2012. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012756-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/media/CDSR/CD012756/urn:x-wiley:14651858:media:CD012756:CD012756-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD012756-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012756.pub2/media/CDSR/CD012756/image_n/nCD012756-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/media/CDSR/CD012756/image_t/tCD012756-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/full#CD012756-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/media/CDSR/CD012756/image_n/nCD012756-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012756-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/media/CDSR/CD012756/urn:x-wiley:14651858:media:CD012756:CD012756-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD012756-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012756.pub2/media/CDSR/CD012756/image_n/nCD012756-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/media/CDSR/CD012756/image_t/tCD012756-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/full#CD012756-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/media/CDSR/CD012756/image_n/nCD012756-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012756-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/media/CDSR/CD012756/urn:x-wiley:14651858:media:CD012756:CD012756-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD012756-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012756.pub2/media/CDSR/CD012756/image_n/nCD012756-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/media/CDSR/CD012756/image_t/tCD012756-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/full#CD012756-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/media/CDSR/CD012756/image_n/nCD012756-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012756-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/media/CDSR/CD012756/urn:x-wiley:14651858:media:CD012756:CD012756-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Bisphosphonate treatment versus placebo , Outcome 1: Change in BMD lumbar spine (%)" data-id="CD012756-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012756.pub2/media/CDSR/CD012756/image_n/nCD012756-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/media/CDSR/CD012756/image_t/tCD012756-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Bisphosphonate treatment versus placebo , Outcome 1: Change in BMD lumbar spine (%) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/references#CD012756-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/media/CDSR/CD012756/image_n/nCD012756-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012756-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/media/CDSR/CD012756/urn:x-wiley:14651858:media:CD012756:CD012756-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Bisphosphonate treatment versus placebo , Outcome 2: Change in BMD distal femur – region 1 (%)" data-id="CD012756-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012756.pub2/media/CDSR/CD012756/image_n/nCD012756-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/media/CDSR/CD012756/image_t/tCD012756-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Bisphosphonate treatment versus placebo , Outcome 2: Change in BMD distal femur – region 1 (%) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/references#CD012756-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/media/CDSR/CD012756/image_n/nCD012756-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012756-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/media/CDSR/CD012756/urn:x-wiley:14651858:media:CD012756:CD012756-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Bisphosphonate treatment versus placebo , Outcome 3: Change in BMD distal femur – region 2 (%)" data-id="CD012756-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012756.pub2/media/CDSR/CD012756/image_n/nCD012756-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/media/CDSR/CD012756/image_t/tCD012756-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Bisphosphonate treatment versus placebo , Outcome 3: Change in BMD distal femur – region 2 (%) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/references#CD012756-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/media/CDSR/CD012756/image_n/nCD012756-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012756-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/media/CDSR/CD012756/urn:x-wiley:14651858:media:CD012756:CD012756-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Bisphosphonate treatment versus placebo , Outcome 4: Change in BMD distal femur – region 3 (%)" data-id="CD012756-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012756.pub2/media/CDSR/CD012756/image_n/nCD012756-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/media/CDSR/CD012756/image_t/tCD012756-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Bisphosphonate treatment versus placebo , Outcome 4: Change in BMD distal femur – region 3 (%) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/references#CD012756-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/media/CDSR/CD012756/image_n/nCD012756-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012756-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Bisphosphonate treatment (oral or intravenous) compared to placebo or no treatment for children under the age of 18 with cerebral palsy (GMFCS levels III to V)</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Bisphosphonate treatment (oral or intravenous) compared to placebo or no treatment for children under the age of 18 with cerebral palsy (GMFCS levels III to V)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> children under the age of 18 with cerebral palsy (GMFCS levels III to V)<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> bisphosphonate treatment (oral or intravenous)<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> </p> <p><b>(Studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo or no treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with bisphosphonate treatment (oral or intravenous)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in BMD lumbar spine</b> </p> <p><i>(%, assessed at 6 months post‐intervention)</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean % change in BMD lumbar spine was 15% (SE ± 5%)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean % change in BMD lumbar spine was 18% larger in the intervention group<br/>(CI 6.57% higher to 29.43% higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in volumetric BMD of distal radius or tibia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured in any trial</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in fracture frequency</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured in any trial</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p><i>(ongoing reporting, up to 6 months post‐intervention)</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>2 of 6 participants receiving their 1st 3‐day pamidronate dosing session had elevated axillary temperature (&gt; 37 °C), but not during any subsequent dosing session. </p> <p>Participants receiving placebo treatment recorded no elevation in body temperature during the 1st dosing session but was noted in 4 subsequent sessions. </p> <p>No differences in white blood cell count were noted between treatment groups.</p> <p>No other adverse events were reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in NTX</b> </p> <p><i>(assessed 4 to 6 months post‐intervention)</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>One study reported that bisphosphonate reduced serum NTX more than placebo; the other study reported that both bisphosphonate and no treatment reduced NTX (r = 0.89, P &lt; 0.001 versus r = 0.69, P = 0.003), but did not compare groups. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in BAP</b> </p> <p><i>(assessed 4 to 6 months post‐intervention)</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>One study reported inconclusive results between groups for BAP. The other study reported that both bisphosphonate and no treatment reduced BAP (r = 0.89, P = 0.02 versus r = 0.72, P = &lt; 0.001), but did not compare groups. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the risk in the placebo or no treatment group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>BAP:</b> bone‐specific alkaline phosphatase; <b>BMD:</b> bone mineral density; <b>CI:</b> confidence interval; <b>GMFCS:</b> Gross Motor Function Classification System; <b>MD:</b> mean difference; <b>NTX:</b> N‐telopeptides; <b>RCT:</b> randomised controlled trial; <b>SE:</b> standard error </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Certainty of evidence was downgraded by two levels, one study was at high risk of bias and one study was at unclear risk of bias.<br/><sup>b</sup>Certainty of evidence was downgraded by one level, as the results included very wide CIs, and the precision of results was deemed to be very low. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Bisphosphonate treatment (oral or intravenous) compared to placebo or no treatment for children under the age of 18 with cerebral palsy (GMFCS levels III to V)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/full#CD012756-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012756-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Unused methods</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Section of Protocol (</b><a href="./references#CD012756-bbs2-0075" title="ZareenZ , McDonnellC , Mc DonaldD , MolloyE . Bisphosphonate use in children with cerebral palsy. Cochrane Database of Systematic Reviews2017, Issue 8. Art. No: CD012756. [DOI: 10.1002/14651858.CD012756]"><b>Zareen 2017</b> </a><b>)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Planned approach</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Why the methods were not used</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Types of outcome measures</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We had planned to collect primary outcomes for the following time points: short‐term (zero to less than one month postintervention), intermediate‐term (one month to less than six months postintervention), and long‐term (equal to or greater than six months postintervention). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were insufficient data from the studies identified to complete this analysis.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of risk of bias in included studies</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We used the Cochrane RoB 1 tool when assessing the risk of bias in each domain for both included studies. Neither study was assessed as having an unclear risk of bias in all domains. In future updates of this review, we will apply the Cochrane RoB 2 tool in assessing the risk of bias for each domain in included studies, and apply the risk of bias due to missing evidence tool in assessing the risk of non‐reported evidence once the final version is released. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The review was conducted prior to the publication of updated guidelines on the assessment of risk of bias in included studies. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Measures of treatment effect</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dichotomous data</b> </p> <p>We had intended to calculate the effect size as a risk ratio, and present it with 95% confidence intervals (CI). We had planned to consider a change as an improvement in bone mineral density (BMD) of the femur (lateral or distal), lumbar spine, and total body minus the head, measured by dual‐Energy x‐Ray absorptiometry (DXA), or volumetric BMD, measured by peripheral, quantitative computerised tomography (pQCT). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study did not identify any relevant dichotomous data.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Continuous data</b> </p> <p>For studies that measured the same outcome using different scales, we had planned to use the standardised mean difference (SMD) with 95% CI. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies used the same measures to assess the outcomes.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Multiple outcomes</b> </p> <p>Had studies provided multiple, interchangeable measures of the same construct at the same point in time, we would have calculated the average SMD across the outcomes and the average estimated variances (<a href="./references#CD012756-bbs2-0031" title="BorensteinM , HedgesLV , HigginsJPT , RothsteinHR . Chapter 24: Multiple outcomes or time-points within a study. In: Introduction to Meta-Analysis. Chichester: John Wiley &amp; Sons, Ltd, 2009.">Borenstein 2009</a>). The aim here would have been to prevent studies that reported on more outcome measures from receiving more weight in an analysis than studies that reported on only a single outcome measure. </p> <p>The effect estimate could have been presented as a mean difference, by transforming the SMD effect estimate backwards to one of the well‐known scales, together with a pre‐defined minimal clinically important difference. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies measuring multiple outcomes were identified in this review.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Unit of analysis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cluster‐randomised trials</b> </p> <p>Had we identified cluster‐randomised trials, we would have sought direct estimates of the effect from an analysis that accounted for the cluster design. If the analysis had not accounted for the cluster design in the cluster trial, we would have used the approximately correct analysis approach, as presented in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012756-bbs2-0044" title="HigginsJPT , EldridgeS , LiT , editor(s). Chapter 23: Including variants on randomized trials. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020a</a>). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any cluster‐randomised trials in this review.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cross‐over trials</b> </p> <p>We had only planned to include cross‐over trials in the meta‐analysis when the data were clear of carry‐over effects. We would have combined the results of cross‐over studies with those of parallel studies by imputing the correlation coefficient from an included study that presented individual participant data, and used this to calculate the standard deviation (SD). We would have used the generic inverse‐variance method to conduct a meta‐analysis of this data (<a href="./references#CD012756-bbs2-0044" title="HigginsJPT , EldridgeS , LiT , editor(s). Chapter 23: Including variants on randomized trials. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020a</a>). To avoid presenting repeated measurements reported in a study, we would have only included data from one time point from an individual study in any single meta‐analysis. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any cross‐over trials in this review.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies with multiple treatment groups</b> </p> <p>Had we identified any studies with multiple treatment groups, we would have combined all relevant intervention groups and compared them with all relevant control groups, making single pair‐wise comparisons. If this approach had not allowed for investigation of intervention‐related sources of heterogeneity, we would have included each intervention arm in separate pair‐wise comparisons, halving the sample size for the control group so to avoid double counting of participants. For dichotomous outcomes, we would have added the number of participants with intervention and the total number of participants, across the groups (<a href="./references#CD012756-bbs2-0044" title="HigginsJPT , EldridgeS , LiT , editor(s). Chapter 23: Including variants on randomized trials. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020a</a>). In case of continuous outcomes, we would have combined the mean and standard deviation using the formulae described in Chapter 10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012756-bbs2-0034" title="DeeksJJ , HigginsJPT , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Deeks 2020</a>). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any studies with multiple treatment groups. All relevant studies were a direct comparison of treatment groups to placebo or standard treatment. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dealing with missing data</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If additional data had been made available, we had planned to include them in the analysis. If we received no response from the study authors, or the data were not made available, we had planned to: </p> <p> <ul id="CD012756-list-0004"> <li> <p>calculate missing summary data (such as missing SD) from CIs, standard errors, P values or t values, where possible, using the methods provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012756-bbs2-0045" title="HigginsJPT , LiT , DeeksJJ , editor(s). Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020b</a>); </p> </li> <li> <p>carry the last observation forward for missing continuous data; and</p> </li> <li> <p>in the case of missing dichotomous data, assume that all missing participants experienced the event. </p> </li> </ul> </p> <p>We also would have specified the methods used to estimate the data in the 'Characteristics of included studies' tables and performed a <a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011780/full#CD011780-sec3-0017" target="_blank">Sensitivity analysis</a> to compare the results of analyses with imputed missing data to those without imputed missing data. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It was not possible to impute missing data in the review.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of heterogeneity</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We had planned to assess statistical heterogeneity between studies by visual inspection of the forest plot for overlapping CI, using the Chi²test for homogeneity with a significance level of α (alpha) = 0.1, and calculating the I² statistic for quantifying inconsistency (estimating the percentage of variation in effect estimates due to heterogeneity rather than sampling error). We would have judged I² values based on the thresholds listed below, as suggested in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012756-bbs2-0034" title="DeeksJJ , HigginsJPT , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Deeks 2020</a>): </p> <p> <ul id="CD012756-list-0005"> <li> <p>0% and 40%: may indicate little heterogeneity;</p> </li> <li> <p>30% and 60%: may indicate moderate heterogeneity;</p> </li> <li> <p>50% and 90% may indicate substantial heterogeneity; or</p> </li> <li> <p>75% and 100% may indicate considerable heterogeneity.</p> </li> </ul> </p> <p>These thresholds can be misleading. Therefore, when considering the importance of I², we would have taken into account the size and direction of effects, and the strength of evidence for heterogeneity based on the P value from the Chi² test or a CI for I². Also, we would have estimated and presented Tau², along with its CI to provide an estimate of the amount of between‐study variation. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not assess statistical heterogeneity in this review as there were insufficient data to conduct a meta‐analysis. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of reporting bias</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Had data from a sufficient number of studies been available (at least 10 studies in a meta‐analysis), we would have drawn funnel plots and tested for funnel plot asymmetry (<a href="./references#CD012756-bbs2-0036" title="EggerM , Davey SmithG . Meta-analysis: potentials and promise. BMJ1997;315(7119):1371–4. [PMC2127866] [PMID: 9432250]">Egger 1997</a>). If we had found any asymmetry of the funnel plot, we would have looked for possible causes (such as publication bias or true heterogeneity) that we might have considered to have a likely influence on the observed effect sizes in our interpretation of the results. However, given that common tests of publication bias lack sensitivity, we would have considered the possible influence that a dominance of small trials might have had on pooled effect sizes in our interpretation, where indicated. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We could not assess reporting bias by drawing funnel plots and testing for funnel plot asymmetry due to an insufficient number of included studies. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Data synthesis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If sufficient data had been included, we would have conducted a meta‐analysis. As we would have expected some heterogeneity in intervention characteristics, we would have pooled the available data using the random‐effects model (<a href="./references#CD012756-bbs2-0034" title="DeeksJJ , HigginsJPT , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Deeks 2020</a>). However, a problem with the random‐effects model is that it assigns the same weight to all studies. Therefore, to test the robustness of our results, we would have conducted a sensitivity analysis using the fixed‐effect model. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We could not complete a meta‐analysis due to insufficient data and so provided a narrative description of the results instead. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Subgroup analysis and investigation of heterogeneity</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We had planned to perform the following subgroup analyses:</p> <p> <ul id="CD012756-list-0006"> <li> <p>dosage of bisphosphonate, since response to treatment will vary with different dosages used; </p> </li> <li> <p>duration of use, since response will vary with the duration of treatment;</p> </li> <li> <p>monotherapy (bisphosphonate only) or multiple treatment (e.g. calcium and vitamin D or alfacalcidol); </p> </li> <li> <p>participant age (e.g. preschool children (aged three to five years) versus school‐age children (aged three to 12 years)); and </p> </li> <li> <p>classification of cerebral palsy according to motor ability, as assessed using the Gross Motor Function Classification System </p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were insufficient data to conduct subgroup analyses.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity analysis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We had planned to perform a sensitivity analysis if there were sufficient data (10 or more studies). Our plan was to: </p> <p> <ul id="CD012756-list-0007"> <li> <p>explore the impact of overall risk of bias on the results, by removing the results of studies deemed to be at high or unclear (or both) risk of bias; </p> </li> <li> <p>explore the impact of missing data for our primary outcomes on the results, by comparing the results of studies with imputed data to studies with no imputed data; and </p> </li> <li> <p>assess the influence of our choice of analysis model on the results from the meta‐analysis, by re‐analysing data using a fixed‐effect model instead of a random‐effects model. </p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not perform a sensitivity analysis due to an insufficient number of included studies. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Unused methods</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/full#CD012756-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012756-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Bisphosphonate treatment versus placebo </span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Change in BMD lumbar spine (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Change in BMD distal femur – region 1 (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Change in BMD distal femur – region 2 (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Change in BMD distal femur – region 3 (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Bisphosphonate treatment versus placebo </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012756.pub2/references#CD012756-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012756.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012756-note-0011">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012756-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012756-note-0009">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD012756-note-0007">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD012756-note-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD012756-note-0010">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD012756-note-0004">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD012756-note-0005">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012756-note-0002">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012756-note-0003">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012756\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012756\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012756\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012756\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012756\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012756\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012756\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012756\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012756\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012756\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012756\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012756\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012756\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012756\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012756\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012756\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012756\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012756\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=kKvAiZoF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012756.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012756.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012756.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012756.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012756.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717636808"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012756.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717636812"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012756.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dbcc76e099371',t:'MTc0MDcxNzYzNy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 